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Abstract
Properly planned and executed clinical trials play a vital role for modern medicine.
They have been considered as the most important studies for the development of novel
treatments. In particular, designs for phase II clinical trials are crucial for new treat-
ments development and assessment since they determine whether further definitive
phase III trials are necessary. Numerous phase II designs have been developed in the
last several decades. In practice, however, investigators usually need to spend time to
create their own statistical algorithms since only a few conventional approaches were
integrated into currently available statistical software. Therefore, developing ready-
to-use packages or tools for phase II designs can accelerate, facilitate, and improve
the process of designing phase II studies. Moreover, most existing phase II designs
were developed in the context of sequential procedures where the main outcome is
a response rate. Such designs may be inefficient when endpoints are not binary and
cannot be observed within a short period. Furthermore, it has been claimed by many
studies that phase II designs with a concurrent control have advantages of better pa-
tient comparability and less bias. In this dissertation, we focus on the non-sequential
designs for two-arm randomized phase II clinical trials. Specifically, the first paper
develops an R package for optimal designs proposed by Mayo et al. (2010) where the
total sample sizes are optimized under pre-specified constraints on the standard errors
of estimated efficacy rates in both control and experimental arms and the difference be-
tween the two rates. However, the designs developed in Mayo et al. (2010) are limited
to dichotomous outcomes only. The second paper generalizes the original methods
to designs suitable for two-arm randomized phase II trials with endpoints from the
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exponential dispersion family. The new designs are generalized from a frequentist
perspective and the total sample sizes are minimized using multiple constraints opti-
mization based on standard errors. This extension is more broadly applicable to other
types of study measures which include several classical distributions such as the nor-
mal, exponential, and gamma as special cases. Recently, the Bayesian analysis has
become a popular and widely accepted approach to statistics due to its flexibility and
ability of incorporating exiting information. The third paper further generalizes the
two frequentist designs to the entire exponential family from a Bayesian perspective
where the total sample sizes are optimized under constraints on the average length of
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1.1 Phase II Clinical Trials
Any planned experiment designed to create preventive, diagnostic, or treatment options for individ-
uals with given medical conditions can be called a clinical trial (Pocock, 2006). It combines rea-
soning from both clinical and statistical perspectives and can be applied in various clinical contexts
in terms of treatment modality including drugs, devices, complementary and alternative medicine,
and prevention (Piantadosi, 2005). Its vital feature is to generalize inferences regarding the results
of a treatment from a limited sample to the general population of patients (Pocock, 2006). In the
field of therapeutic drug development, clinical trials usually consist of four phases. Phase I trials
primarily aim to test for drug safety, such as toxicity and acceptable drug dosage, based on only a
small number of individuals. Phase II trials also include a small number of patients for which both
the safety and pilot effectiveness are of interest. In the much larger phase III studies, researchers
formally compare new treatments with alternatives, no therapy, or placebo. Finally, adverse effects
and additional large-scale, long-term studies of morbidity and mortality are monitored after new
drugs are approved by the Food and Drug Administration (FDA) for marketing in phase IV trials
(Piantadosi, 2005; Pocock, 2006).
As explained above, a phase III trial usually requires a large sample size for evaluating effi-
cacy and safety. This means that such trials are lengthy and expensive. Therefore, in practice,
the phase III comparative testing will not be implemented unless positive evidence of safety and
effectiveness is demonstrated in early phase trials (Piantadosi, 2005; Pocock, 2006). In addition, as
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claimed by Piantadosi (2005), careful planning leads to a good study design and execution, which
themselves lead to high-quality evidence about the new treatment effectiveness. Therefore, the
planning, design, and quality of phase II clinical trials are important for new treatments develop-
ment and assessment since they determine whether further definitive phase III trials are necessary
(Pocock, 2006).
The term phase II clinical trial is used in a large range of studies. The simplest phase II trial
design is the single-arm pilot study where the same treatment is assigned to all patients with neither
concurrent control group nor variation in dose or treatment regimen included (Zohar et al., 2008).
This type of phase II design is commonly used in the oncology area owing to reasons that the
standard therapies may be unsuccessful and the placebo control is unethical to use (Biswas et al.,
2007). Such a design may still be considered preferable even when the ethical problem of using
control arm does not exist. This is because that, under this design, as many as possible subjects can
be enrolled into the experimental arm with the given small sample size and the historical control
data are often available for comparison (Biswas et al., 2007).
Adding a concurrent control arm is sometimes attractive and necessary for phase II designs.
There are some reasons for this: first, situations for the historical control such as patient popu-
lation and imaging technologies may be very different from those for the current study; second,
when phase II trials aim to evaluate some new cytostatic biologic agents, instead of employing the
traditional endpoints such as the response rate used in historical control, other alternative endpoints
such as the progression-free survival are more appropriate; third, the classic single-arm phase II
designs cannot separate trial effects such as patient selection, assessment schedule, treatment loca-
tions, etc. from the treatment effect on clinical outcomes, thus leading to multiple sources of bias
(Mandrekar & Sargent, 2010). Therefore, some authors including Rubinstein et al. (2005), Wieand
(2005), Taylor et al. (2006), Rubinstein et al. (2009), and Mandrekar & Sargent (2010) suggest
the randomized phase II trial design due to its advantages of better patient comparability and less
selection and outcome-trial effect bias.
The sequential designs further increase the complexity of phase II clinical trials. This type of
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designs is important in early phase trials since it incorporates the ethical need into considerations
by allowing trials stopping early due to futility or being unsafe (Stallard & Thall, 2001). In such
designs, in addition to make a decision about whether the new treatment is promising for further
investigation in a randomized phase III trial at the end of a study, a decision of whether the trial
should be terminated early must also be made at each interim analysis. However, the sequential
design may require a long study duration when the outcome cannot be observed in a timely fashion
(e.g., survival or disease progression) (Mayo et al., 2010). Furthermore, several doses or treatment
regimens (either with or without a control arm) can be included into the design of phase II trials
where additional decision regarding which dose or treatment is the best must be made. Studies of
this type are called the screening designs.
This dissertation focuses on optimal designs for the non-sequential two-arm randomized phase
II clinical trials due to their potential advantages in the practice of medical research including
greater compatibility to non-rapidly observable outcomes, better patient comparability, and less
selection and outcome-trial effect bias. Specifically, in this dissertation, we first develop an R
package for the optimal designs proposed in Mayo et al. (2010) applicable to single-stage two-
arm randomized phase II clinical trials with binary outcomes. We then generalize the original
approaches to the context of the exponential family from both frequentist and Bayesian perspec-
tives. Therefore, section 1.2 of this chapter explains why an R package is developed for Mayo
et al. (2010) designs. The differences in philosophy between frequentist and Bayesian approaches
to sample size determination are discussed in section 1.3. Section 1.4 illustrates and summarizes
the motivations and structure of this dissertation.
1.2 Why Develop a Package in R
Clinical trials are very important for the development of successful novel treatments. In practice,
however, there is no uniform statistical method for designing and analyzing clinical studies since
each trial has its own particular structure and goals (Piantadosi, 2005). This is also true in phase
II trials where numerous designs were developed in the past several decades. Therefore, unless
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a conventional design for which existing computer program is available for immediate use can
be tailored to fit a particular trial, investigators often need to spend time to develop their own
algorithms.
There are many statistical software and languages available of which SAS and R are probably
the two most popular statistical programming languages. SAS is commonly used to conduct data
analyses, power calculations, and sample size estimations in clinical studies. However, it provides
limited procedures or macros in the phase II setting. The PROC POWER procedure in SAS provides
computations for sample size and power based on the Fisher’s exact test. Groulx et al. (2007)
created SAS macros %SIMON and %ADAPTIVE for Simon’s two-stage designs (Simon, 1989) and
Lin and Shih’s adaptive design (Lin & Shih, 2004), respectively. A different macro named phase2
for Simon’s two-stage designs (Simon, 1989) was developed by Cantor & Moffitt Cancer Center
(2009). In addition, unlike some other lower level languages such as FORTRAN and C++ which
require users having in-depth knowledge of computer programming, SAS is not very flexible for
developing innovative methods.
R is widely used for the designs and analyses of clinical trials by researchers from academia,
government agencies, and the pharmaceutical industry since its release (Chen & Peace, 2010). It
is an open source software that not only permits modifications on source codes to handle various
applications but also is quite powerful for new methods development. It can be compiled and run
on various of systems including UNIX platforms, windows, and MAC OS. Currently, numerous
R packages have been written and published for clinical trial applications among which, unfortu-
nately, only a few are specific for phase II clinical trial designs. The R package named clinfun is
frequently used for both design and analysis of phase II clinical trials (Chen & Peace, 2010). It
contains functions for computing effect size, sample size, and power based on the Fisher’s exact
test, the two-stage boundary operating characteristics, Simon’s two-stage optimal and minimax de-
signs (Simon, 1989), and the exact single-stage design. It can also be used for defining a stopping
rule and its corresponding operating characteristics for the repeated significance testing based on
monitoring toxicity. In addition, the function of sample size determination for the group sequential
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design in the context of phase III trials is included in the clinfun package (Chen & Peace, 2010).
Besides SAS and R, some other high level graphical user interface statistical software such
as SPSS, Minitab, and JMP can also be used to conduct some standard analyses on clinical trial
data. However, they provide very little support for the designs and sample size computations in the
context of phase II trials.
As discussed above, statistical software specific for phase II trial designs are limited to several
conventional approaches. In order to accelerate, facilitate, and improve the process of designing
phase II studies, it is necessary to develop ready-to-use tools based on different types of phase II
clinical trials. Mayo et al. (2010) developed optimal designs for single-stage two-arm randomized
phase II clinical trials which minimize the total sample sizes by placing multiple constraints on
proportion estimates in both control and experimental arms and the difference between proportion
estimates using standard errors. A SAS macro code was provided to their designs and is available
upon request from the authors. Because R is another commonly and widely used statistical pro-
gramming language, we develop an R package for the designs proposed in Mayo et al. (2010) in
this dissertation.
1.3 Frequentist and Bayesian Approaches for Sample Size Determination
Conducting phase II clinical trials requires a lot of preparation, among which sample size deter-
mination is one of the most important calculations because it not only has influence on a trial’s
conclusions and implications but also affects the length and budget (Fosgate, 2009; Zhang et al.,
2011). In the past several decades, many different statistical methods have been developed for
sample size optimization of phase II studies. They can be classified in terms of two philosophies
of statistical thoughts - frequentist and Bayesian. Literature reviews for the phase II clinical trial
designs from a frequentist perspective are discussed in sections 2.1 and 3.1. For references to
phase II Bayesian designs, readers are referred to section 4.1. In this section, we review the sta-
tistical philosophies of both frequentist and Bayesian approaches, as well as their advantages and
disadvantages associated with sample size determination.
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The frequentist approach for determining sample size is most common (Chung & Schulz,
2007). It is broadly implemented in phase II trials and widely accepted by both medical journals
and the regulators such as the FDA. In general, statistical methods from a frequentist perspective
assume that the parameters of interest on which inferences center are unknown but not random,
thus no prior probability distribution is associated with them. Therefore, the frequentist approach
defines probabilities in terms of the data space and makes the inferences based on a particular ex-
periment (Berry et al., 2010). When designing phase II trials, the frequentist approach utilizes prior
information by estimating the values of unknown parameters according to literature, expert knowl-
edge, or some pilot studies (Chung & Schulz, 2007). The sample size is usually determined in
terms of the specified goal such as minimizing variance or maintaining adequate power (Maxwell
et al., 2008).
One advantage of the frequentist approach is that it provides sample size determination some
systematic and widely accepted operating characteristics such as the power and Type I error. These
characteristics are very important to regulators such as the FDA (Berry et al., 2010). Moreover,
because the frequentist approach does not require additional specification of prior densities, the
statistical models and equations for sample size calculation are often straightforward and easy to
understand and use. In addition, the frequentist approach usually does not require high computa-
tional cost and gives a standard route to evaluating the performance of a wide range of statistical
methods.
A key limitation in principle to the frequentist approach is that it does not consider the uncer-
tainty involved in estimating unknown parameters. When determining sample sizes for phase II
trials, frequentist methods require particular values of unknown parameters which are not observ-
able and need to be estimated according to external information. Misspecification of these values
may lead to less than optimal designs and invalid inferences. Some limitations also arise when an
early termination plan is necessary for a phase II trial due to the ethical or economic considerations.
Although the sequential monitoring is possible in the frequentist setup, the frequentist approach
is not very flexible to possible changes that could occur during a study. One reason is that the
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error rates are affected by the inclusion of several interim analyses, so interpretations of statistical
inferences are less apparent (Biswas et al., 2007; Berry et al., 2010). Some authors developed
strategies for choosing stopping rules in order to control the type I error rate; for examples, see
Pocock (1977), O’Brien & Fleming (1979), and Fleming et al. (1984).
The Bayesian approach is becoming popular lately owing to its flexibility and ability of incor-
porating existing information. In general, statistical methods from a Bayesian perspective assume
the parameters of interest having prior distributions by which summary information for unknown
parameters is provided prior to collecting data. Based on data once observed, prior probabilities
are updated to posterior distributions for statistical inference. In other words, the posterior distribu-
tion combines the prior knowledge and data information of unknown parameters, so the inferences
made from Bayesian methods include all information currently available (Berry et al., 2010). In
addition, the Bayesian method is inherently adaptive, so it is not necessary to define a sample size
in advance (Berry et al., 2010). However, Mayo & Gajewski (2004) and guidelines from FDA for
the use of Bayesian statistics in medical device clinical trials suggest that a pretrial sample size
should be determined according to safety and effectiveness endpoints (Food and Drug Administra-
tion, 2010). When designing phase II trials, the Bayesian approach utilizes external information by
assigning prior distributions to the parameters of interest. The sample size is usually determined
in terms of either the decision-theoretic criterion or the inferential-theoretic criterion (see section
4.1).
One advantage of the Bayesian approach is that it allows the direct use of probability distribu-
tions on the parameters of interest, thus taking the uncertainty associated with all unknowns into
considerations. Another advantage is its flexibility in possible design modifications during a trial.
As explained in section 1.1, the sequential design is sometimes important in early phase trials be-
cause termination plans may be necessary due to ethical or economic considerations (Stallard &
Thall, 2001). The Bayesian approach is flexible in that stopping a trial early does not influence
the credibility of Bayesian inferences and modifications can be made in terms of accumulated in-
formation at any time during a study (Berry et al., 2010). Furthermore, because the main purpose
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of phase II trials is to evaluate whether a therapy or therapies are sufficiently effective and safe to
warrant a larger and more expensive phase III study (Piantadosi, 2005; Pocock, 2006), designing
a phase II clinical trial can be treated as a decision problem (Stallard, 1998; Biswas et al., 2007;
Berry et al., 2010). The Bayesian approach is ideal for such situations since the costs and benefits
involved in decision making can be assessed using the utility or loss function defined under the
Bayesian decision-theoretic criterion (Berry et al., 2010).
The greatest concern to the Bayesian approach is the question of “objectivity”. Before com-
puting the sample size, a prior distribution must be selected for all unknown parameters, and the
posterior distributions thus the results can be heavily influenced by the chosen priors. In prac-
tice, however, there is no uniform way to select prior densities, meaning that different researchers
may suggest different prior distributions. Therefore, eliciting a prior that properly reflects ex-
perts’ beliefs is very challenging and considered as the most crucial step in the Bayesian analysis
(Spiegelhalter et al., 2004). Cautions should be taken when eliciting prior distributions or mislead-
ing results may be produced. Moreover, the Bayesian approach usually involves high-dimensional
integrals for which closed form solutions often do not exist. In this case, the posterior densities are
estimated using the simulation-based approaches such as the Markov Chain Monte Carlo (MCMC).
These methods, however, produce random errors in results and often lead to high computational
costs. Some limitations also arise from the flexibility of the Bayesian approach. The first one is
that deviations from the original plan can harm some study conclusions (Berry et al., 2010; Maha-
jan & Gupta, 2010). Such flexibility may also prompt difficulties in controlling the overall type I
error rate (Mahajan & Gupta, 2010). Besides, although the Bayesian approach is useful in solving
decision making problem, clinical trial designs based on decision-theoretic methods are relatively
uncommon in practice (Berry et al., 2010). One reason is that it is difficult to specify a good utility
or loss function that satisfies the study’s specific objectives (Adcock, 1988; Berry et al., 2010).
As discussed above, both frequentist and Bayesian approaches to sample size determinations
have their advantages and disadvantages. In this dissertation, we first generalize the original de-
signs proposed in Mayo et al. (2010) for binomial distributions only to the exponential dispersion
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family of distributions from a frequentist perspective. Given that the frequentist approach may
not be the best when the clinicians, for example, can only provide a range of values for the study
parameters, we further generalize the two frequentist designs to the entire exponential family from
a Bayesian perspective. Under different situations, each method has its own advantages and limi-
tations. We do not advocate for using one approach over the other.
1.4 Current Studies
In the process of developing new treatments, statistics play an important and non-ignorable role
since the success and quality of clinical trial researches are significantly affected by the statistical
plan employed. In this dissertation, we focus on improving the statistical practice and design for
single-stage two-arm randomized phase II trials.
Because well-designed phase II trials can improve the success rate in much more expensive
phase III studies, a good deal of phase II designs were developed in the literature. In practice,
it is impossible to propose an uniform design that is suitable for all types of phase II trials since
each of them has its own particular structure and goals (Piantadosi, 2005). Tailoring a design to
accommodate a particular trial at hand is difficult and time consuming, often requiring the use
of computer algorithm (Thall, 2008). As discussed in section 1.2, there is a need for developing
more ready-to-use packages or tools that can accelerate, facilitate, and improve phase II studies.
SAS and R are the two most popular and widely used statistical software tools for the designs
and analyses of clinical trials. Since the SAS macro has been already provided to the optimal
designs proposed in Mayo et al. (2010), we develop an R package for the original designs in this
dissertation.
The classic phase II trial designs only contain one arm, and a same treatment is assigned to
all enrolled patients. Such designs may cause problems of bias since situations in previous studies
may be different in many aspects from those in the current trial. Including a concurrent control
arm into phase II clinical trials is sometimes attractive and necessary because it creates less bias
and has advantages of better patient comparability (Rubinstein et al., 2005; Mandrekar & Sargent,
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2010). Moreover, most existing designs for phase II studies were developed based on the sequen-
tial procedures that allow for incorporating the ethical and economy needs into considerations.
These designs, however, could be lengthy and may not be appropriate for phase II trials where
endpoints cannot be observed within a short period (Mayo et al., 2010). Mayo et al. (2010) de-
veloped the optimal designs for single-stage two-arm randomized phase II clinical trials where the
total sample sizes are minimized using constraints optimization. Their designs overcome the obsta-
cles described above, but are limited to the dichotomous endpoint. Many probability distributions
from the exponential family are important in the practice of phase II clinical trials. For example,
the normal distribution is useful when a phase II trial has continuous endpoints such as the change
in tumor size; the exponential and gamma distributions are important for phase II studies with time
to event outcomes such as the time to disease progression. Therefore, it is necessary to develop op-
timal designs more broadly applicable to phase II clinical studies with endpoints from distributions
in the exponential family.
Over the last 10 to 20 years, the improvement of modern computing power and the development
of the MCMC algorithm for sampling lead to the explosion of interest in Bayesian analysis (Berry
et al., 2010). It offers a flexible way to integrate all exiting information into designs and analyses
of phase II clinical trials. Unlike the frequentist method that assumes unknown parameters having
fixed values, the Bayesian approach allows for uncertainty in all unknowns. Therefore, it would be
worthy and beneficial to develop Bayesian optimal designs for single-stage two-arm randomized
phase II studies.
The remainder of this dissertation is organized as follows. In chapter 2, an R package named
Sample.Size is developed for the optimal designs proposed in Mayo et al. (2010). The application
of this package is explained with two examples. In chapter 3, the original approaches specific
for binary outcomes are generalized from a frequentist perspective to designs suitable for single-
stage two-arm randomized phase II trials with endpoints from the exponential dispersion family.
Its implementations are provided for multiple design considerations under the Poisson, negative
binomial, normal, and exponential distributions. Chapter 4 further generalizes the two frequentist
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designs to the entire exponential family from a Bayesian perspective where the total sample sizes
are optimized in terms of the average length of posterior credible intervals. An illustrative exam-
ple of method implementation is provided for the exponential distribution. Sample sizes are also
calculated for the normal and Bernoulli distributions using two real-life phase II clinical trials. We
conclude this dissertation with summary and future studies in chapter 5.
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Chapter 2
An R Package for Sample Size Determination Using Optimal Designs with Mul-
tiple Constraints
by Wei Jiang, Jonathan D. Mahnken, and Matthew S. Mayo
Abstract
Previous literature (Mayo et al., 2010) proposed optimal designs for two-arm randomized phase
II clinical trials where the total sample sizes are minimized under multiple constraints using the
standard errors of the estimated event rates. The designs are applicable for trials with dichotomous
endpoints, and can be applied to trials with or without fixed randomization allocation ratios. In this
article, an R package named Sample.Size for conducting the methodologies developed by Mayo
et al. (2010) is provided and explained. Two examples of package implementations are provided.
Key words: R package; Optimal design; Sample size; Standard error.
2.1 Introduction
Clinical trials usually consist of four phases, among which the analysis and the quality of the
design of phase II trials are important for the development and assessment of a new treatment
because the conclusions derived from phase II trials are determinative regarding whether further,
definitive phase III trials are necessary (Pocock, 2006). Sample size calculation is crucial for the
design of phase II clinical trials since it impacts the timelines through recruitment goals and the
required budget of trials (Fosgate, 2009; Zhang et al., 2011).
Often, single-arm single-stage phase II studies can be designed to get an estimate on response
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rate with a given level of precision; however, such a design may lack an effective termination plan
when treatment is not sufficiently effective and have no control arm for comparison (Mayo et al.,
2010). A termination plan is desired for the ethical and practical (e.g., budgetary) considerations,
while including a concurrent control arm can protect against bias such as that exists in comparison
with historical controls (Rubinstein et al., 2009). Many authors provided single-arm multi-stage
phase II designs to avoid the disadvantage of lack of the termination plan; see Gehan (1961), Simon
(1989), Chen et al. (1994), Herndon (1998), Sargent et al. (1999), and Friedman et al. (2010).
But these designs may be inefficient in recruiting subjects for studies where outcomes cannot be
observed until several months after treatment (Mayo et al., 2010). Moreover, some publications
discussed designs with concurrent control including Jung (2008), Thall & Cheng (1999), Thall &
Cheng (2001), Sun et al. (2009), Wason et al. (2012), and Wason & Mander (2012). However,
all these randomized designs optimized the total sample size in the context of group-sequential
procedures where the allocation ratio at each stage is one-to-one. This is undesired when the
control arm, for example, is known to be expensive and inefficient. Under such situations, the
unbalanced design may be preferred.
Mayo et al. (2010) developed single-stage randomized phase II designs in the context of al-
location ratio optimization motivated by the research goal that of estimation within precision
boundaries for both response rates (in treatment and control arms) and on the rate difference.
In this paper, a new R package called Sample.Size is provided to calculate optimized sample sizes
using the designs proposed in Mayo et al. (2010). Sample.Size can be obtained from CRAN
at http://cran.r-project.org/web/packages/Sample.Size/. The function available in this package is
called Sample.Size, which is presented and described in section 2.4.
Section 2.2 of this manuscript summarizes the optimal designs proposed by Mayo et al. (2010).
Section 2.3 discusses the method of specifying values of upper bounds on multiple constraints from
that work. Examples of the Sample.Size package are presented in Section 2.4. We conclude with
a brief summary and considerations for future directions.
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2.2 Optimal Designs with Multiple Constraints
In this section, we review the optimal designs proposed by Mayo et al. (2010) for randomized phase
II trials which consist of a control and an experimental arm, denoted by C and E, respectively.
If YC and YE are assumed to be the number of responders for arm C and arm E, then they are
two independent binomially distributed random variables with parameters (nC,πC) and (nE ,πE),
respectively, where ni and πi correspond, respectively, to the sample size and assumed true event
probability for arm i, i∈ {C,E}. The assumed true efficacy difference between two arms is denoted
by ∆ = πE −πC, so if the outcome represents being cured, the efficacy of arm E is superior to that
of arm C if ∆ is positive, whereas a negative value of ∆ corresponds to the superiority of arm C
compared to arm E.
2.2.1 Design constraints
It is well known that the maximum likelihood estimators of efficacies in control and experimental
arms (i.e., πC and πE) and their difference (i.e., ∆= πE−πC) are given by π̂C =YC/nC, π̂E =YE/nE
and ∆̂ = π̂E − π̂C, respectively (Casella & Berger, 2002). The proposed designs optimize the total
sample size, N = nC +nE , by assuring that the response in each arm and their difference are esti-
mated with pre-specified precision using standard errors. More specifically, the three constraints
under which the minimum total sample size is obtained are:
SE (π̂C) =
√
πC (1−πC)/nC ≤ γC,
SE (π̂E) =
√







πC (1−πC)/nC +πE (1−πE)/nE ≤ γ∆,
where γC,γE and γ∆ are pre-specified upper bounds on the standard errors listed above with 0 ≤
γC,γE ≤ 0.5 and 0 ≤ γ∆ ≤
√
0.5. These three inequalities can be expressed in terms of nC and nE
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as:
nC ≥ πC (1−πC)/γ2C, (2.1)
nE ≥ πE (1−πE)/γ2E , (2.2)







It has been shown by Mayo et al. (2010) that the equation of total sample size, N = nC + nE , is
minimized under constraints (2.1) and (2.2) when n′C = πC (1−πC)/γ2C and n′E = πE (1−πE)/γ2E .
In order to minimize the equation of N = nC + nE under constraint (2.3), nE is first replaced






, and then the standard strategy that taking the
derivative of N with respect to nC and setting the result equal to zero is implemented. This leads to














The optimal designs proposed by Mayo et al. (2010) can be applied to trials with or without fixed
randomization allocation ratios, which are discussed in the next two sections.
2.2.2 Fixed ratio design
For the case of fixed allocation ratio, the optimized total sample size must satisfy both constraints
(2.1) - (2.3) and the randomization relationship nC = rnE , where r = c/e is the pre-specified fixed
allocation ratio. Notice that both c and e are assumed to be positive integers with the greatest
common divisor being 1 (i.e., relative prime). It can be shown that a two-dimensional point with
positive integer coordinates whose ratio satisfies r = c/e belong to the set {(cd,ed) ;d = 1, ...,∞}
(Mayo et al., 2010). Therefore, with known c and e, the point with optimized sample size is
derived by finding the smallest integer value of d that satisfies constraints (2.1) - (2.3). Such d
can be obtained by first substituting cd and ed for nC and nE in inequalities (2.1) - (2.3), and then
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is the smallest integer value of d that satisfies constraints (2.1) - (2.3), and hence the desired point
with the smallest sample size that satisfies both the allocation ratio and the three constraints is
(cdmax,edmax).
2.2.3 Optimal ratio design
For the case of optimal allocation ratio, the optimized total sample size is determined by diverse







∩ (n∗E > n′E)
}
. This scenario implies that the optimal sample size is
completely determined by constraint (2.3) and thus the point that minimizes N = nC + nE under






(see Figure 2 in Mayo et al. (2010)). Since these two coordinates
of this point are not necessarily positive integers, possible candidates for the optimal sample size
are
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(see Figure 3 in Mayo et al. (2010)). Due to the same reason that





















are two possible candidates for the optimal sample size. The desired point is the latter if it satisfies







∩ (n∗E ≤ n′E)
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and n′E is determined by constraint
(2.2) (see Figure 4 in Mayo et al. (2010)). Similar to scenarios above, two possible candidates for





















and the desired point is the one that satisfies all three constraints or the one has the smaller coordi-





∩ (n∗E ≤ n′E)
}
. The optimal sample size obtained under the last sce-
nario is completely determined by constraints (2.1) and (2.2) (see Figure 5 in Mayo et al. (2010)).
























and Ceiling [n∗E ] are first substituted for c and e in equation (2.4) and then dmax is
calculated. This point violates constraints (2.1) - (2.3) only if dmax > 1. The assessment of other
points follows a similar approach. For more details on the methodology development, see Mayo
et al. (2010).
2.3 Specification of Upper Bounds on Standard Errors
In practice, values of upper bounds on standard errors for constraints (2.1) - (2.3) should be spec-
ified carefully, because the required sample size relies directly on these values. Poor estimation
is a result if the trial is inadequately sized, whereas unnecessarily small bound values lead to a
longer duration and a more expensive trial. It requires communication between statisticians and
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investigators when defining the precision levels of estimates. For investigators who are not fa-
miliar with statistics, instead of considering the values of standard error itself, they may prefer
the expression that the parameters of interest vary within a specified radius (say 0.05). In such
cases, values of upper bounds on standard errors can be specified by using the margin of error
of corresponding asymptotic confidence intervals, where narrow 100(1−α)% confidence inter-
val provides more certainty regarding the location of the true response than wider intervals. An
asymptotic 100(1−α)% confidence interval for a parameter π is (Agresti, 2014)
π̂±margin of error = π̂± zα/2SE (π̂) ,
where zα/2 is the 100(1−α/2)% quantile of standard normal distribution. Suppose one would
like the 100(1− α)% confidence interval of a parameter π to be ±l or narrower, that is the
margin of error = zα/2SE (π̂) ≤ l. This leads to the inequality that SE (π̂) ≤ l/zα/2. Therefore,
the upper bound on standard error γ is of the following form:
γ = l/zα/2.
Values of upper bounds on standard errors for constraints (2.1) - (2.3) specified using the strategy
explained in this section is described with examples in the next section.
2.4 Usage Examples
A new R package Sample.Size is provided to calculate optimal sample sizes for two-arm phase
II clinical trials using the approaches proposed in Mayo et al. (2010). In order to illustrate the
functionality of the main function Sample.Size of this package, two detailed examples are pre-




Suppose that, in a two-arm phase II oncology study, the response rate for the standard of care is 0.2,
and a new treatment is expected to have a response rate of 0.4. A researcher seeks to determine the
sample size to estimate each individual efficacy with a standard error of no greater than 0.1 and the
difference with a standard error of no greater than 0.15. This design question can be accomplished
by using the function Sample.Size, whose usage with complete arguments is given as follows,
Sample.Size(pi_c , pi_e , gamma_c , gamma_e , gamma_delta ,
Allratio_c = NA , Allratio_e = NA).
The arguments pi_c and pi_e are the assumed response rates for control and experimen-
tal arms, respectively. The values of gamma_c, gamma_e, and gamma_delta represent, respec-
tively, the upper bounds on the standard errors for constraints (2.1) - (2.3). The smaller values
of gamma_c, gamma_e, and gamma_delta, the more precise the estimates. One may specify the
values of Allratio_c and Allratio_e to define the allocation ratio of control arm to experi-
mental arm (i.e., allocation ratio = Allratio_c/Allratio_e). Default values of Allratio_c and
Allratio_e are both NA that represents missing values in R. If one leaves these two values blank,
the output only includes required sample sizes for optimal and one-to-one allocation designs. De-
tailed description of these arguments can also be attained using the command ??Sample.Size.
Once the package Sample.Size is installed on the local computer, for the above example, one
needs to type the following:
> library (Sample.Size)
> Size1 <- Sample.Size (0.2 , 0.4, 0.1, 0.1, 0.15 , 1, 2)
Then the output is:
Specified values for parameters :
Response rates:
control = 0.2 experiment = 0.4
Upper bounds for constriants :
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gammaC = 0.1 gammaE = 0.1 gammaDelta = 0.15
Required sample sizes:
[1] Optimal Design:
nc = 16 ne = 24 n = 40
[2] 1 to 1 Allocation Design:
nc = 24 ne = 24 n = 48
[3] 1 to 2 Allocation Design:
nc = 16 ne = 32 n = 48
When upper bounds of standard errors on constraints (2.1) - (2.3) are 0.1, 0.1, and 0.15, respec-
tively, the optimal ratio design would enroll 40 subjects in total from which 16 would be random-
ized to the standard of care and 24 would be assigned to the experimental arm, and one-to-one and
one-to-two allocation ratio designs would both require a total of 48 subjects. Be aware that the
output includes the computed sample sizes for the optimal and one-to-one allocation ratio designs
by default. If designs with other allocation ratios are desired, one needs to specify the values of
Allratio_c and Allratio_e. In our example, Allratio_c = 1 and Allratio_e = 2, thus the
sample size for one-to-two allocation ratio design is calculated. Sometimes, one may want to esti-
mate individual efficacies and their difference more precisely. In such cases, smaller upper bounds
of standard errors on constraints (2.1) - (2.3) need to be used (e.g., see below).
> Size2 <- Sample.Size (0.2 , 0.4, 0.05 , 0.08 , 0.125 , 1, 2)
Specified values for parameters :
Response rates:
control = 0.2 experiment = 0.4
Upper bounds for constriants :




nc = 64 ne = 38 n = 102
[2] 1 to 1 Allocation Design:
nc = 64 ne = 64 n = 128
[3] 1 to 2 Allocation Design:
nc = 64 ne = 128 n = 192
In this case, constraints chosen for constraints (2.1) - (2.3) are 0.05, 0.08, and 0.125, respectively.
The total sample sizes required for the optimal, one-to-one, and one-to-two designs are 102, 128,
and 192, respectively. As expected, more subjects are required for all three designs since the
constraints for standard errors are more stringent here. For illustrative purposes, we also compute
the sample sizes when the efficacy rate for the control arm is low as 0.05 and that for the treatment
arm is 0.15, and constraints and allocation ratio are the same as Size1.
> Size3 <- Sample.Size (0.05 , 0.15 , 0.1, 0.1, 0.15 , 1, 2)
Specified values for parameters :
Response rates:
control = 0.05 experiment = 0.15
Upper bounds for constriants :
gammaC = 0.1 gammaE = 0.1 gammaDelta = 0.15
Required sample sizes:
[1] Optimal Design:
nc = 5 ne = 13 n = 18
[2] 1 to 1 Allocation Design:
nc = 13 ne = 13 n = 26
[3] 1 to 2 Allocation Design:
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nc = 7 ne = 14 n = 21
The total sample sizes needed for the optimal, one-to-one, and one-to-two allocation ratio designs
are 18, 26, and 21, respectively. As we can see, the required sample sizes under the same con-
straint criteria increase while response rates of both arms approach 0.5 for all three randomization
schemes.
2.4.2 Example 2
We now consider a two-arm phase II oncology study where patients with esophageal cancer are
treated with chemotherapy in control arm and with a new inhalable dry powder treatment in the
experimental arm. The response rate for the standard of care is 0.35, and a new treatment is
expected to have a response rate of 0.5. Researchers want to estimate each individual efficacy with
a margin of error no greater than 0.15 and the difference with a margin of error no greater than 0.2.
Using the formula developed in Section 2.3 with α = 0.05, the upper bounds for constraint (2.1)
and (2.2) are both 0.15/1.96= 0.077, and the upper bound for constraint (2.3) is 0.2/1.96= 0.102.
Therefore, we type in the following:
> Size4 <- Sample.Size (0.35 , 0.5, 0.077 , 0.077 , 0.102 , 1, 2)
Then the optimal sample sizes are:
Specified values for parameters :
Response rates:
control = 0.35 experiment = 0.5
Upper bounds for constriants :
gammaC = 0.077 gammaE = 0.077 gammaDelta = 0.102
Required sample sizes:
[1] Optimal Design:
nc = 45 ne = 47 n = 92
22
[2] 1 to 1 Allocation Design:
nc = 46 ne = 46 n = 92
[3] 1 to 2 Allocation Design:
nc = 39 ne = 78 n = 117
A total of 92 subjects are needed for the optimal ratio design in which 45 and 47 would be ran-
domized, respectively, to the standard of care and the experimental arms. In addition, one-to-one
and one-to-two allocation ratio designs would require 92 and 117 subjects in total, respectively.
2.5 Summary and Future Directions
The Sample.Size package computes the required sample sizes using the optimal designs with
multiple constraints proposed in Mayo et al. (2010). The methods are designed for two-arm ran-
domized phase II clinical trials, and the required sample size can be optimized either using fixed
or optimal randomization allocation ratios. The computation time of Sample.Size is very fast,
usually does not exceed several seconds for most of the home computers. The designs can esti-
mate individual response rates and their difference with various levels of precision using different
combinations of constraints. In general, more stringent constraint criteria lead to larger sizes of
sample; and notably, flexible allocation ratio can have smaller sample size requirements in various
settings.
This package can also be used to design studies when only one or two of these constraints
are needed. For example, if one wants to compute the sample size required for estimating the
difference of response rates with pre-specified level of precision, we can define the upper bound of
constraint (2.3) using the value that meets the desired precision, and using large upper boundaries
of other two constraints (2.1) and (2.2). Thus, the resulting sample sizes are only affected by the
constraint placing on the difference of response rates. A similar process can be followed when
computing the sample sizes in the context of employing constraint(s) on an individual arm only, or
on both arms but not on the difference.
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One limitation to the designs proposed in Mayo et al. (2010) is that their methods are only
applicable to dichotomous endpoints. We are working on generalizing the original approaches
from being limited to binary endpoints to allow for outcomes from the exponential family. This
future extension will be more broadly applicable to other types of study measures which include
several classical distributions, such as the normal, exponential, and Poisson as special cases.
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Chapter 3
Generalized Optimal Designs for Two-Arm Randomized Phase II Clinical Tri-
als with Endpoints from the Exponential Dispersion family
by Wei Jiang, Jonathan D. Mahnken, Jianghua He, and Matthew S. Mayo
Abstract
For two-arm randomized phase II clinical trials, previous literature proposed optimal designs that
minimize the total sample sizes under multiple constraints on the precision of the estimated event
rates and their differences. The original designs are limited to trials with dichotomous endpoints.
This paper extends the original methods to phase II clinical trials with endpoints from the expo-
nential dispersion family distributions. The proposed optimal designs minimize the total sample
sizes needed to provide estimates of population means of both arms and their difference with pre-
specified precision. Sample sizes are calculated for multiple design considerations for outcomes
from specific distribution families.
Key words: Multiple constraints; Optimized design; Sample size; Standard error.
3.1 Introduction
Phase II clinical trials assess both the safety and pilot effectiveness of new therapies (Pocock,
2006). It traditionally recruits a small number of patients only to the experimental arm, and the
evaluated drug efficacy and safety are compared with those of a historical control (Jung, 2013).
However, such traditional single-arm phase II designs may not be appropriate since patient pop-
ulations in previous studies may be different in many aspects from the population in the current
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trial. In addition, there are situations where very limited historical data for an existing standard
therapy are available, which may be particularly true when the disease progression instead of tu-
mor response is used as the outcome for phase II trials (Rubinstein et al., 2005). Because of these
issues, Mandrekar & Sargent (2010) claimed that comparing a new study with a historical control
could be questionable, and the randomized phase II design is recommended.
Multiple methods have been proposed for optimal designs for two-arm randomized phase II
clinical trials. Thall & Cheng (2001) developed an optimal two-stage design based on safety and
efficacy using a class of tests proposed by Thall & Cheng (1999) to minimize either the mean
sample size or the maximum sample size with constraints on type I and type II errors. Jung (2008)
describes a two-stage design based on testing whether the experimental arm has a higher response
rate than the control arm. Sun et al. (2009) introduced a two-stage two-arm randomized design
for oncology trials based on both tumor responses and early progression rates with the sample size
determined by a generalization of Simon’s (Simon, 1989) optimal and minimax design. Wason
& Mander (2012) proposed a δ -minimax design for two-stage two-arm trails with continuous
endpoints that minimizes the maximum expected sample size. This design was extended by Wason
et al. (2012) to trials with more than two stages.
The term optimal for these publications is used in the context of group-sequential procedures
where a one-to-one allocation ratio is performed at each stage. Multi-stage designs are sometimes
inefficient in enrolling subjects especially when outcomes will not occur until several months af-
ter treatment. Furthermore, unbalanced designs often may be beneficial, especially when unequal
distribution of either research or treatment costs exists between study groups. Some references in
the literature discussed optimization in the context of allocation ratio; see Walter (1977), Brittain
& Schlesselman (1982), Fazal (1983), Blackwelder (1986), Brooks (1987), Farrington & Manning
(1990), and Sahai & Khurshid (1996). However, none of these publications present designs specifi-
cally for phase II randomized trials for which only a limited number of patients are available. Mayo
et al. (2010) proposed single-stage optimal designs for two-arm randomized phase II clinical trials
with dichotomous endpoints to minimize the total sample size with respect to the allocation ratio.
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Their designs control precision levels of the estimated proportions in each arm and the difference
between the estimated proportions. Specifically, the total sample sizes are minimized by giving
individual upper bounds to the standard errors of efficacy rates of the control and experimental
arms, as well as to the standard error of the difference of efficacy rates between arms.
Many probability distributions from the exponential family, such as the Bernoulli, normal,
Poisson, negative binomial, exponential, and gamma distributions are important in the practice
of phase II clinical trials. The binary response, defined as whether or not a patient responds to
treatment, is one commonly used dichotomous outcome in phase II studies. Quite often, such
a binary outcome is dichotomized from an underlying continuous response. For example, the
RECIST criterion measured by a function of the change in tumor size is used for classifying a
cancer patient’s response to treatment into a binary response (Eisenhauer et al., 2009). However,
such dichotomizing loses information (Farewell et al., 2004; Karrison et al., 2007). The normal
distribution is useful in phase II clinical trials when the underlying continuous response is analyzed
directly; see Karrison et al. (2007), Whitehead et al. (2009), and Wason & Mander (2012) for
examples. Responses in many phase II clinical trials are in the form of counts, for example,
magnetic resonance imaging lesion counts and clinical relapse counts in multiple sclerosis patients
(Verhey et al., 2013), person-time response rate in breast cancer patients (O’Brien et al., 1996),
and peritonitis incidence in peritoneal dialysis patients (Gadola et al., 2013). For these cases,
the Poisson distribution or the negative binomial distribution can be employed. Another type of
responses commonly encountered in phase II clinical trials is the time-to-event outcome, for which
some examples can be found in Ameri et al. (1993), Sanson et al. (1996), Ameri et al. (1997), and
Burtness et al. (2014). In this case, the exponential distribution or the gamma distribution can be
used. Therefore, it is worthy to develop optimal designs for phase II clinical trials with endpoints
from distributions in the exponential family. In this paper, we extend the work of Mayo et al.
(2010) for dichotomous endpoints to the exponential dispersion family.
Section 3.2 of this paper describes the generalized optimal designs that place multiple con-
straints on the precision levels of mean estimates of both arms and their difference. This section
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is divided into two parts including fixed ratio design and optimal ratio design. In section 3.3, the
implementations of the proposed optimal designs are provided for the Poisson, negative binomial,
normal, and exponential distributions. The total sample sizes are optimized under the optimal ratio
design, as well as under one-to-two, two-to-one, and one-to-one randomization for all examples.
Associated advantages and limitations of the generalized designs are discussed in section 3.4.
3.2 Generalized Optimal Designs
Throughout this paper, we denote the dispersion parameter, sample size, estimate of mean, and the
standard error of the estimate as φ , n, µ̂ , and SE(µ̂), respectively. More explicitly, φC, nC, µ̂C, and
SE(µ̂C) are used for the control arm, and φE , nE , µ̂E , and SE(µ̂E) are used for the experimental
arm. In addition, the difference between mean estimates and its standard error are denoted by
∆̂ = µ̂C− µ̂E and SE(∆̂), respectively. The population mean is denoted by µ , thus using µC and µE
for the control and experimental arms, respectively. Their difference is denoted by ∆.
3.2.1 Exponential dispersion family
Before describing the generalizations of the designs proposed by Mayo et al. (2010), some fun-
damental definitions and results regarding the exponential dispersion family need to be illustrated.
We closely follow the discussion in Agresti (2014). Let Y be a random variable from a distribution
in the exponential dispersion family, which has probability mass or density function of the form







where φ is the dispersion parameter, and θ is the natural parameter. It can be shown that the
general expressions for the mean and variance of the exponential dispersion family distributions
are E(Y ) = ψ ′(θ) and var(Y ) = a(φ)ψ ′′(θ) = a(φ)g(µ), respectively. This indicates that the
function ψ(.) determines the moments of Y . The maximum likelihood estimator of the population
mean E(Y ) is the sample mean, that is µ̂ = µ(θ̂) = 1n ∑
n
i=1Yi. When µ(θ) is an invertible function,
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This section discusses the generalized optimal designs for outcomes in the exponential dispersion
family where the sample sizes are minimized by providing pre-specified precision to the mean
estimates of both treatments and their difference. Specifically, the designs control the precision
of the mean estimates in each arm and their difference by applying constraints on their standard
errors. Therefore, our goal is to minimize the total sample size, defined by N = nC + nE , under
given constraints SE(µ̂C) ≤ γC, SE(µ̂E) ≤ γE , and SE(∆̂) ≤ γ∆. Note that both nC and nE are
positive integers. With the standard errors defined previously, the total sample size N is minimized



















where γ∆, γC, and γE are all assumed to be positive. Both aC(φC)gC(µC) and aE(φE)gE(µE) can
be zero; however, this happens only when the endpoint is a degenerate random variable which is
not of interest here. Therefore, both aC(φC)gC(µC) and aE(φE)gE(µE) are assumed to be positive.
These three constraints can be written equivalently as:
nC ≥ aC(φC)gC(µC)/γ2C (3.1)
nE ≥ aE(φE)gE(µE)/γ2E . (3.2)
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Because both nC and nE are positive integers, the boundary defined by constraint (3.3) is not func-
tional unless it is larger than zero. Since the values of aE(φE)gE(µE), γ2∆, and aC(φC)gC(µC)n
−1
C
are all positive, constraint (3.3) is meaningful only if nC > aC(φC)gC(µC)/γ2∆.
It has been shown in Mayo et al. (2010) that, for positive real numbers nC and nE , points that
minimize N = nC +nE are located along the bounds defined in constraints (3.1) - (3.3); therefore,
the minimum value for nC under constraint (3.1) is n′C = aC(φC)gC(µC)/γ
2
C, and the minimum value
for nE under constraint (3.2) is n′E = aE(φE)gE(µE)/γ
2
E . Minimum values of nC and nE based on
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constraint (3.3) are obtained by implementing a similar strategy to that discussed in Mayo et al.
(2010). Specifically, we first define the boundary function by replacing nE and ≥ with f (nC) and
= in constraint (3.3), respectively. The resulting function is







where nC > aC(φC)gC(µC)/γ2∆. The shape of this function can be determined by its several proper-
ties including that: the limit of f (nC) as nC decreases in value approaching aC(φC)gC(µC)/γ2∆ is in-
finity, the limit of f (nC) when nC goes to infinity is aE(φE)gE(µE)/γ2∆, f
′(nC)< 0, and f ′′(nC)> 0.
Therefore, as shown in Figure 3.1, the boundary function f (nC) defined by constraint (3.3) goes
to infinity when nC approaches aC(φC)gC(µC)/γ2∆ from the right, it decreases monotonically to-
wards aE(φE)gE(µE)/γ2∆ as nC approaches infinity, and it is a convex function over the range
nC > aC(φC)gC(µC)/γ2∆. Possible candidates for nC that minimize N under constraint (3.3) are



































Since constraint (3.3) is defined over the range nC > aC(φC)gC(µC)/γ2∆, the solution to the









The second derivative of nC + f (nC) with respect to nC verifies that n∗C obtained from equation






is the point that minimizes N under






E may not be integers.
Similar to the designs proposed by Mayo et al. (2010), in the context of the generalized optimal
designs, subjects can be randomly assigned to two arms of a phase II clinical trial either with or
without a fixed allocation ratio. We call the first scheme the fixed ratio design and the second
scheme the optimal ratio design, which are discussed in details in the following sections.
3.2.3 Fixed ratio design
For the fixed ratio design, the numbers of subjects assigned to the control and experimental arms
are constrained by the ratio r = c/e, where both c and e are positive integers with the greatest
common divisor being one (i.e., relative prime). This indicates that the desired point (nC,nE) with
positive integer coordinates needs to satisfy the relationship nC = rnE in addition to constraints
(3.1) - (3.3) in such a design. It has been shown in Mayo et al. (2010) that a two-dimensional
point with coordinates satisfying the ratio r = c/e belong to the set {(cd,ed) : d = 1,2,3, ...,∞}.
Utilizing a similar method to that discussed in Mayo et al. (2010), d′, the smallest integer value for
d that satisfies constraints (3.1) - (3.3), is obtained by first substituting cd and ed for nC and nE in
inequalities (3.1) - (3.3), respectively, and solving each for d, and then rounding the maximum d















and d′ = Ceiling(dmax). With c and e known, the point of minimum sample size satisfying the
allocation ratio r = c/e and constraints (3.1) - (3.3) is therefore (nC,nE) = (c∗d′,e∗d′).
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3.2.4 Optimal ratio design
In many situations, the optimal ratio design may be beneficial since, compared with the fixed ratio
design, it can lead to fewer subjects, thus potentially improving the economic efficiency. In this
section, we develop the optimal ratio design using an analytic and a grid search methods.
3.2.4.1 Analytic method
For the optimal ratio design, the minimum sample size N is determined under various combinations
of constraints (3.1) - (3.3) when there is no randomization constraint. The values of aC(φC)gC(µC)
and aE(φE)gE(µE), and the bounds γC, γE , and γ∆ determine under which constraint or constraints







) is obtained by utilizing equation (3.4) and the boundary function





minimum value for nE under constraint (3.2) (i.e., n′E) is aE(φE)gE(µE)/γ
2





either greater or not greater than n′C and n
′
















































As shown in subgraph (a) of Figure 3.2, the minimum sample size is completely determined by
constraint (3.3), implying that n∗C obtained from equation (3.4) and n
∗
E = f (n
∗
C) minimizes N.
Given that n∗C + n
∗






produces a point with
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positive integer coordinates that satisfies constraints (3.1) - (3.3) (Mayo et al., 2010). However,
this point has the potential to produce a total sample size one observation larger than the true
minimum sample size under the design constraints owing to the monotone decrease of f (nC) and







point (i.e., point with the minimum sample size under the design constraints), it is possible that(
Ceiling[n∗C]−1,Ceiling[n∗E ]+1
)
that produces the same total sample size, for example, also sat-
isfies constraints (3.1) - (3.3). Therefore, candidates of optimal points under the first case have the
form of
(Ceiling[n∗C]− kC−m1,Ceiling[n∗E ]− kE +m1) ,(kC,kE) ∈ K,m1 ∈M1,
where
K = {(kC,kE) ∈ {0,1}×{0,1};0≤ kC + kE ≤ 1}
and
M1 = {m1 ∈ Z;−Ceiling[n∗E ]+ kE < m1 <Ceiling[n∗C]− kC,(kC,kE) ∈ K} .
Here Z is used to denote the set of integers. Using this expression, we first let m1 = 0 and assess
whether points resulted from (kC,kE) = (0,1) and (1,0) satisfy constraints (3.1) - (3.3), and then
we search values for m1 to produce an optimal set in which every point has the minimum total
sample size and satisfies the design constraints.
The second case,
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In this case, subgraph (b) of Figure 3.2 suggests that n′C = aC(φC)gC(µC)/γ
2
C defined under con-
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with given n′C minimize N. In general,
n′C + n
′′






could generate a total sample size one
observation larger than the true minimum sample size under the design constraints; and some other
points with the same total sample size may satisfy the design constraints as well. Therefore, can-
didates for the minimum total sample size follow the form of
(
Ceiling[n′C]−m2,Ceiling[n′′E ]− kE +m2
)
,kE ∈ {0,1},m2 ∈M2,
where M2 =
{
m2 ∈ Z;−Ceiling[n′′E ]+ kE < m2 <Ceiling[n′C],kE ∈ {0,1}
}
. Using this expression,






when m2 = 0 and kE = 1 satisfies
constraints (3.1) - (3.3), then the set of optimal points are obtained by evaluating whether candidate


























As shown in subgraph (c) of Figure 3.2, in this case, n′E = aE(φE)gE(µE)/γ
2
E defined under












}−1. Because of the same reasons stated




,kC ∈ {0,1},m3 ∈M3,
where M3 =
{
m3 ∈ Z;−Ceiling[n′E ]< m3 <Ceiling[n′′C]− kC,kC ∈ {0,1}
}
. The set of optimal
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As shown in subgraph (d) in Figure 3.2, the minimum sample size is completely determined un-










is the desired point.
In this paragraph, we perform an approach similar to that discussed in Mayo et al. (2010) to
assess whether a point,
(
Ceiling[n′′C]− kE −m3,Ceiling[n′E ]+m3
)
for example, satisfies constraints
(3.1) - (3.3). Evaluations of other points can be done a similar manner. To begin with, we substitute
Ceiling[n′′C]−kE−m3 and Ceiling[n′E ]+m3 for c and e in r = c/e, respectively. This suggests that
r = (Ceiling[n′′C]− kE −m3)/(Ceiling[n′E ] +m3) but the greatest common divisor of them is not
forced to be one, which is different from the situation in the fixed ratio design. Then dmax is
computed using equation (3.5) by following the same process as described in section 3.2.3. The
point
(
Ceiling[n′′C]− kE −m3,Ceiling[n′E ]+m3
)
satisfies constraints (3.1) - (3.3) if dmax is less than
or equal to one.
We have demonstrated that multiple optimal points with the same minimum total sample size
may be produced for the first three cases discussed above. Mathematically, the optimal points
obtained using the strategy proposed in Mayo et al. (2010) have the minimum (or the two smallest)
Lp distance(s) (i.e., ||x−y||p = (∑i |xi− yi|p)1/p) to the actual points minimizing N. These points
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Figure 3.2: Point with the smallest sample size for four cases. Constraint (3.3) (solid line) and
constraints (3.1) and (3.2) (dashed lines).
also coincide with the ones derived above with m’s equal to zero. In the second case, for example,









Lp distance compared to those with nonzero values of m2.
3.2.4.2 Rapid grid search method
For the optimal ratio design, instead of identifying optimal points using the analytic method de-
scribed previously, another stable and reliable method for finding the minimal sample size is the
grid search, a numerical method utilized widely in optimization problems. The standard grid
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search, however, can be extremely slow since it evaluates all combinations of sample sizes of
control and experimental arms. Due to this additional computational burden and cost, in this sec-
tion, we propose a rapid grid search method that can tremendously reduce the grid points searched
in the sample size space and efficiently enhance the computational speed.
Figure 3.3 shows the process of the proposed rapid grid search method for the optimal ratio








, the minimum sample size
determined under constraints (3.1) and (3.2), we add one sample at a time to the experimental





next moves towards right by adding one sample to n0C and decreasing one sample from n
1
E and then
makes subsequent searches downwards by withdrawing one sample at a time from the experimental
arm until it falls below f (n1C) = f (n
0
C +1). The grid point right before nE falls below f (n
1
C) yields
a second optimal candidate (n1C,n
2





1, ...,k) by repeating this procedure, we stop searching the next grid point if nkE − 1 is less than
either Ceiling[n′E ] or f (n
k−1
C +1). The desired optimal set contains those optimal candidates with







the starting value n0E is larger than f (n
0
C). The algorithm of the rapid grid search method is given
below:













is the optimal design. If not, go to step 2.
Step 2: nE = nE +1, and go to step 3.
Step 3: If nE < f (nC), go back to step 2. If not, go to step 4.
Step 4: If nE − 1 < f (nC + 1) or nE − 1 < Ceiling[n′E ], then stop and go to step 6. If not,
(nC,nE) = (nC +1,nE −1), and go to step 5.
Step 5: If nE−1 > f (nC), then nE = nE−1. Keep going until nE−1 < f (nC), then go back
to Step 4.
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Figure 3.3: Procedure for rapid grid search method.
Step 6: Output those grid points with the smallest total sample size.
Observe that both the analytic and grid search methods may lead to multiple optimal points,
and their resulting optimal sets should be identical to each other. Thus the optimal ratio design
may give investigators many options, and depending on situations and objectives of phase II trials,
one may be preferred over the others. For example, investigators may choose the one that assigns
more subjects to the less expensive arm to reduce the trial budget. One advantage of the analytic
method is that it computes the optimal point much faster than the method of rapid grid search; both
methods, however, can be employed in practice.
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3.2.5 Some properties of the generalized optimal designs
In previous sections, the fixed ratio and optimal ratio designs were developed. Some of their
properties are discussed in this section.
Property 1. If γE = γC, γ2∆ ≥ γ2E + γ2C = 2γ2C, and the variances of two arms are equal, the total
sample size obtained under the optimal ratio design is generally the same as that obtained under
one-to-one randomization, except that the former sometimes is 1 less than the latter.
The second case of optimal ratio design,
{
(n∗C ≤ n′C)∩ (n∗E > n′E)
}
, is used to demonstrate this





























































for one-to-one randomization design. Therefore, the optimal total sample size for the second case
of optimal ratio deisgn is Ceiling[n′C]+Ceiling[n
′′




E ]− kE . Since
kE ∈ {0,1}, this completes the proof. It can be shown similarly that property 1 also holds for the
third case of optimal ratio design. Neither assumption γ2
∆
≥ γ2E + γ2C nor γE = γC is needed in order




C)∩ (n∗E > n′E)
}
, since






E are all equal to {2aC(φC)gC(µC)}/γ2∆ which does not depend on
γC and γE . Property 1 is valid for the fourth case of optimal ratio design,
{




regardless of whether γ2
∆
≥ γ2E + γ2C or not.
Property 2. Increasing the variance of one arm with the variance of the other arm fixed, or
increasing variances of both arms leads to an increase in the total sample size.




C)∩ (n∗E > n′E)
}
, is used to demonstrate this
property, where n∗C and n
∗









is resulted from either larger values


































It can be shown similarly that property 2 is valid for the fixed ratio design and other cases of optimal
ratio design. Note that if gC(µC) and gE(µE) are increasing functions of µC and µE , respectively,
then larger values for µC or µE or both lead to larger total sample size.
Property 3. The total sample size obtained from the optimal ratio design is always the mini-
mum.





C)∩ (n∗E > n′E)
}
, with that determined by the fixed ratio design with
one-to-one allocation ratio (i.e., c = e = 1). Suppose that aE(φE)gE(µE) ≥ aC(φC)gC(µC), then












This is because the assumption n∗C > n
′




than aC(φC)gC(µC)/γ2C. Now denote the minimum N resulted from one-to-one fixed ratio design
as N], and let N∗ = n∗C +n
∗
























Comparing other cases of the optimal ratio design with the fixed ratio design can be shown simi-
larly.
3.3 Implementation Examples
Section 3.2 discusses the generalized optimal designs for two-arm randomized phase II clinical
trials which optimize the total sample sizes under constraints on standard errors of estimates of
the population means and their difference. In this section, we first discuss strategies for specify-
ing constraints on standard errors. The implementations of the proposed designs on the Poisson,
negative binomial, normal, and exponential distributions are then given. The total sample sizes
are minimized under the optimal ratio design, as well as under one-to-two, two-to-one, and one-
to-one randomization ratios for each example distribution. Both the analytic and the rapid grid
search methods are evaluated. Results from the analytic method are computed using macro code
programmed in SAS 9.3. The rapid grid search algorithm is programmed in R 3.0.2.
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3.3.1 Specification of constraints on standard errors
In practice, communications between statisticians and investigators are crucial when performing
the proposed optimal designs because the resulting minimum sample sizes heavily depend on val-
ues of upper limits of constraints (3.1) - (3.3). Inefficiently large values of constraints lead to
inadequately sized trials thus poor estimation, whereas lengthy and expensive trials are resulted
from unnecessarily small limits. Therefore, careful evaluations are required when specifying these
values. Sometimes, specifying limits on standard errors directly is not straightforward for investi-
gators who are not familiar with statistics. If this is the case, these values can be specified using
margin of errors of corresponding asymptotic confidence intervals. For example, if an investigator
believes that the mean survival time of a disease should vary within a radius of 5 months, its stan-
dard error can be computed from a 100(1−α)% confidence interval with lower and upper limits
been µ̂−5 and µ̂ +5, respectively. Mathematically, an asymptotic 100(1−α)% Wald confidence
interval for a parameter µ is defined as (Casella & Berger, 2002)
µ̂± zα/2SE(µ̂),
where zα/2 represents the 100(1−α/2)% quantile of standard normal distribution. Suppose that
a parameter of interest is expected to have a 100(1−α)% confidence interval with length of 2l or
narrower, this suggests that SE(µ̂) is less than or equal to γ = l/zα/2.
3.3.2 Poisson distribution
The Poisson distribution arises naturally when the endpoint of a phase II study takes the form of
counts; for example, the person-time incidence of diseases is interested in many clinical studies. In
the context of Poisson distributions, we have aC(φC) = φC = 1, gC(µC) = µC, aE(φE) = φE = 1, and
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Unlike the normal distributions which have separate parameters for mean and variance, the
variance of a Poisson distributed variable is equal to its expectation, implying that the difference
between means affects the magnitude of the total sample size. For illustrative purposes, the optimal
designs are carried out with µC equal to 5, 20, 30, and 40, and the value of ∆ ranging from 0 to 4
by increments of 2 for µC = 5, ranging from 0 to 8 by increments of 4 for µC = 20, and ranging
from 0 to 16 by increments of 8 for µC ≥ 30. The values chosen for γC and γE for constraints (3.1)
and (3.2), respectively, are both 1.22 such that both ratios, γ2C/µC and γ
2
E/µE , are less than or equal
to a common value 0.3. The value of γ∆ for constraint (3.3) is set to be 1.77 and 1.48 in order to
make both the 90% and 95% Wald confidence intervals for (µC− µE) have a margin of error no
greater than 2.9.
Table 3.1 lists the optimized sample sizes computed using parameter values defined above;
that is, γC = γE = 1.22 and γ∆ = 1.48 and 1.77. For each set of parameters considered, minimum
sample sizes are derived under the one-to-two, two-to-one, one-to-one, and optimal ratios. Note
that the total sample sizes produced by one-to-two allocation ratio are identical with the ones under
two-to-one allocation when two arms have equal variance. This is because that constraints (3.1)
and (3.2) have the same pre-specified limits (i.e., γC = γE). In some cases, the minimum sample
size is achieved by more than one designs. For example, when µC = 20, µE = 28, and γ∆ = 1.48,
the total sample size is 44 for both optimal and one-to-one allocation ratios. For many parameter
sets considered, the optimal ratio design gives multiple optimal points. When µC = 30, µE =
46, and γ∆ = 1.48, for example, the optimal set consists of (33,36), (32,37), (31,38), (30,39),
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and (29,40). This gives investigators more options, and which one is preferred over the others
depends on situations and objectives of clinical studies. When the precision level under constraint
(3.3) (i.e., γ∆) decreases to 1.77, the resulting total sample sizes are generally smaller than the
ones obtained when γ∆ = 1.48. For instance, if variances of control and experimental arms are
30 and 38, respectively, the optimal ratio, one-to-two, two-to-one, and one-to-one would require
enrolling, respectively, 47, 63, 78, and 52 subjects when γ∆ is equal to 1.77. Except for the two-
to-one allocation ratio, the total sample sizes of others are all smaller than the ones resulted from
γ∆ = 1.48. The rapid grid search method is performed using µC = 30, µE = 46, γC = γE = 1.22,
and γ∆ = 1.48, for which searching process is displayed in Figure 3.4. Identical results with the
analytic method are obtained.
3.3.3 Negative Binomial distribution
The negative binomial distribution is recommended for count or frequency data with overdisper-
sion (i.e., the variance of the outcome variable exceeds the mean), because the Poisson model may
underestimate the standard errors (Berk & MacDonald, 2008). For the negative binomial distribu-
tion, we have aC(φC) = φC = 1, gC(µC) = µC(1+kC), aE(φE) = φE = 1, and gE(µE) = µE(1+kE).



















As is the case with the Poisson distribution, the difference between means affects the total
sample size for the negative binomial distribution. For illustrative purposes, the same parameter
values as those used in the Poisson example were chosen except that variances were inflated by
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Figure 3.4: Rapid grid search procedure for Poisson distribution with µC = 30, µE = 46, γC =
γE = 1.22, and γ∆ = 1.48. The vertical line corresponds to the minimum value determined under
constraint (3.1) (i.e., n′C). The horizontal line corresponds to the minimum value determined under
constraint (3.2) (i.e., n′E). The decreasing concave curve corresponds to the boundary function
determined under constraint (3.3) (i.e., f (nC)).
10% (i.e., kC = kE = 0.1) to account for overdispersion. Specifically, the values chosen for µC are
5, 20, 30, and 40. The values chosen for ∆ are from 0 to 4 by increments of 2 when µC = 5, from
0 to 8 by increments of 4 when µC = 20, and from 0 to 16 by increments of 8 when µC ≥ 30.
Computed sample sizes for the negative binomial outcomes are given in Table 3.2. Observe
that the results under the Poisson and the negative binomial models follow a similar pattern, except
that the resulting total sample sizes from the negative binomial model are larger than those from
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the Poisson model due to the inflated variances. When performing the optimal ratio design with
γ∆ = 1.48, µC = 20, and µE = 28, for example, a trial would enlist 48 subjects for the negative
binomial model among which 23, 22, or 21 patients and 25, 26, or 27 patients would be assigned
to the control and experimental arms, respectively. In contrast, only 44 subjects would be enrolled
if the Poisson model is used, where (22,22), (21,23), (20,24), (19,25), and (18,26) are five
different allocation schemes. In addition, Figure 3.5 shows the searching process of the rapid grid
search method for the negative binomial distribution when µC = 30, µE = 46, γC = γE = 1.22, and
γ∆ = 1.48 are employed.
Notice that the proposed designs do not require two arms having the same distribution fam-
ily. When encountering the situation that an overdispersion exists in only one arm, the negative
binomial distribution can be used to model the arm having overdispersion with the other remained
Poisson. Suppose that in a phase II clinical study, for example, researchers believe that the most
appropriate choice of means are 20 and 28 for the control and experimental arms, respectively, and
the variance of the experimental arm is about 10% higher than its mean. With specified design
constraints being γC = γE = 1.22 and γ∆ = 1.48, 46 subjects would be enrolled using the optimal
ratio design among which 21 or 20 subjects would be randomized to the control arm and 25 or
26 subjects would be randomized to the experimental arm; on the other hand, one-to-two, two-
to-one, and one-to-one allocation ratio designs would require enrolling 51, 63, and 48 subjects,
respectively.
3.3.4 Normal distribution
As discussed above, the normal distribution is useful when a continuous endpoint is of interest such
as the change in tumor size. When the optimal designs are performed on the normal distributions,
we have aC(φC) = φC = σ2C, gC(µC) = 1, aE(φE) = φE = σ
2
E , and gE(µE) = 1, revealing that the










Figure 3.5: Rapid grid search procedure for negative binomial distribution with µC = 30, µE = 46,
γC = γE = 1.22, and γ∆ = 1.48. The vertical line corresponds to the minimum value determined
under constraint (3.1) (i.e., n′C). The horizontal line corresponds to the minimum value determined
under constraint (3.2) (i.e., n′E). The decreasing concave curve corresponds to the boundary func-











In the context of normal distribution, the difference between means is not related to the mag-
nitude of total sample size since the variance and mean in this case are independent of each other.
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For illustrative purposes, the values chosen for σ2C are 5, 10, and 20, and the value of σ
2
C −σ2E
ranges from −4 to 4 by increments of 2 when σ2C = 5, and ranges from −8 to 8 by increments of
4 when σ2C ≥ 10. The values chosen for γC and γE for constraints (3.1) and (3.2), respectively, are
both 0.77 such that both ratios, γ2C/µC and γ
2
E/µE , are less than or equal to a common value 0.3.
The value of γ∆ for constraint (3.3) is set to be 1.10 and 0.92 in order to make both the 90% and
the 95% Wald confidence intervals for (µC−µE) have a margin of error no greater than 1.8.
Resulting minimum sample sizes under the one-to-one, one-to-two, two-to-one, and optimal ra-
tios when γC = γE = 0.77 and γ∆ = 0.92 and 1.10 are listed in Table 3.3. Suppose that the variances
of control and experimental arms in an actual study are expected to be 20 and 24, respectively. If
γ∆ for constraint (3.3) is 1.10, then the optimal ratio design would require recruiting, respectively,
34 and 41 individuals (75 subjects in total) to the control and experimental arms; on the other hand,
the one-to-two, two-to-one, and one-to-one allocation ratios would require enrolling 102, 123, and
82 subjects, respectively. The rapid grid search method for the normal distribution is performed us-
ing σ2C = 10, σ
2
E = 18, γC = γE = 0.77, and γ∆ = 0.92, for which the searching process is displayed
in Figure 3.6. It produces results identical with those using the analytic method.
3.3.5 Exponential distribution
In phase II clinical trials, the exponential distribution is commonly used to model the time-to-event
response and other continuous, positive, time-scaled variables. From its density function, we can
see that aC(φC) = φC = 1, gC(µC) = µ2C, aE(φE) = φE = 1, and gE(µE) = µ
2
E . This implies that















Figure 3.6: Rapid grid search procedure for normal distribution with σ2C = 10, σ
2
E = 18, γC =
γE = 0.77, and γ∆ = 0.92. The vertical line corresponds to the minimum value determined under
constraint (3.1) (i.e., n′C). The horizontal line corresponds to the minimum value determined under
constraint (3.2) (i.e., n′E). The decreasing concave curve corresponds to the boundary function






The variance of an exponentially distributed random variable is equal to the square of its mean,
revealing that the total sample size is affected by the difference of group means. For illustrative
purposes, the values chosen for µC are 10, 20, and 30, and the value of ∆ ranges from 0 to 4 by
increments of 2 when µC = 10, and ranges from 0 to 8 by increments of 4 when µC ≥ 20. The
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E , are not greater than a common value 0.3. The value of γ∆ for constraint
(3.3) is set to be 8.23 and 6.89 in order to make both the 90% and the 95% Wald confidence
intervals for (µC−µE) have a margin of error no greater than 13.5.
The optimal sample sizes listed in Table 3.4 are produced using γC = γE = 5.48, and γ∆ = 6.89
and 8.23 under the one-to-one, one-to-two, two-to-one, and optimal ratios. Suppose that a two-
arm phase II clinical trial with an exponential outcome is now enrolling subjects. If γ∆ = 8.23,
µC = 20, and µE = 28 are specified during the planning stage, under the optimal ratio design, this
trial would require matriculating 41 subjects among which 14 individuals would be randomized
to the control arm and 27 individuals would be randomized to the experimental arm; on the other
hand, 42, 81, and 54 subjects would be enrolled, respectively, for the one-to-two, two-to-one,
and one-to-one allocation designs. The rapid grid search method for the exponential distribution is
conducted using µC = 30, µE = 38, γC = γE = 5.48, and γ∆ = 6.89, for which the searching process
is displayed in Figure 3.7. It produces results identical with those using the analytic method.
3.4 Discussion
In this paper, the optimal designs for two-arm randomized phase II clinical trials with dichotomous
endpoints proposed by Mayo et al. (2010) are generalized to trials with endpoints from the expo-
nential dispersion family. The generalized optimal designs control the precision of mean estimates
of both arms and their difference by applying constraints on their standard errors.
Several properties associated with the proposed designs are discussed in section 3.2.5. Property
1 points out that, under some conditions, the optimal ratio design is balanced (i.e., one-to-one)
when the variances of two arms are equal; property 2 suggests that larger variances in one or both
arms lead to a larger total sample size. These two properties are intuitively true since a larger
sample size is required to obtain the same precision as the variances increase. Property 3 shows
that the optimal ratio design always has the smallest possible sample size. This also follows our
expectation because this optimal ratio is designed to minimize the total sample size.
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Figure 3.7: Rapid grid search procedure for exponential distribution with µC = 30, µE = 38, γC =
γE = 5.48, and γ∆ = 6.89. The vertical line corresponds to the minimum value determined under
constraint (3.1) (i.e., n′C). The horizontal line corresponds to the minimum value determined under
constraint (3.2) (i.e., n′E). The decreasing concave curve corresponds to the boundary function
determined under constraint (3.3) (i.e., f (nC)).
The proposed designs use the difference between means as the measurement of associations.
Notably, other approaches also exist, such as the difference between log means for Poisson and the
ratio of means for the exponential distribution. The reason we use difference between means to
measure the association in this article is that it is commonly used and it allows us to derive exact
variances for all three constraints since often only limited sample are available in phase II settings.
In the example section, the limits for constraints (3.1) - (3.3) can be obtained from the standpoint
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of Wald confidence intervals. This does not mean that the proposed designs depend on the large
sample approximation. Instead, compared with using the standard error directly, the expression of
estimating the parameter of interest within a specified radius may be easier for investigators who
are less familiar with statistics to understand. This is just an alternative way for specifying the
upper limits of standard errors. In addition, both the analytic and the rapid grid search methods
can be performed on the optimal ratio design; however, the analytic method allows us to compute
the minimum sample size more efficiently. Sometimes, multiple optimal points are produced by
the optimal ratio design. This gives more options to the investigators. Depending on different
considerations, such as the cost and ethics, one may be preferred over the others.
The proposed designs are beneficial and limited in multiple aspects. In terms of advantages,
first of all, the generalized approaches are very flexible in that both optimal and fixed ratio designs
are allowed. For the one-to-two allocation ratio, the speed of recruitment may be accelerated by
the fact that more subjects are willing to enroll in a study, especially when the standard of care
is not successful (Mayo et al., 2010). Second, a variety of types of endpoints, such as the count
data, dichotomous endpoints, and exponential outcomes, can be handled by the optimal designs,
as long as the distributions of these endpoints belong to the exponential dispersion family. Third,
the approaches do not force the outcomes in two arms belonging to the same distribution family.
Therefore, some complicated situations, such as the overdispersion, can be handled by the designs.
In addition, the generalized optimal designs can be easily implemented using current software
such as SAS and R, so they can be readily applied when a randomized two-arm phase II clinical
trial is conducted. On the other hand, one disadvantage of the proposed designs is that they are
constructed based upon the exponential dispersion family. For some distributions from the more
general exponential family, such as the beta distribution, the proposed methods may not work.
In addition, as of all frequentist approaches, the generalized optimal designs require particular
values of unknown parameters in order to compute the sample sizes. Misspecification of means
and variances may lead to a less than optimal design.
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Table 3.1: Minimum sample sizes when γC = γE = 1.22 under 1 to 2, 2 to 1, 1 to 1, and optimal
randomization allocation ratios for Poisson distribution.
µC µE γ∆ 1 to 2 2 to 1 1 to 1 Optimal (nC,nE)
5 5 1.48 12 12 10 10 (6,4) (5,5) (4,6)
5 7 1.48 12 15 12 11 (5,6)
5 9 1.48 15 21 14 13 (6,7) (5,8)
20 20 1.48 42 42 38 37 (20,17) (19,18) (18,19)
(17,20)
20 24 1.48 45 51 42 41 (22,19) (21,20) (20,21)
(19,22) (18,23) (17,24)
20 28 1.48 48 57 44 44 (22,22) (21,23) (20,24)
(19,25) (18,26)
30 30 1.48 63 63 56 55 (29,26) (28,27) (27,28)
(26,29)
30 38 1.48 69 78 64 62 (30,32) (29,33) (28,34)
30 46 1.48 75 93 70 69 (33,36) (32,37) (31,38)
(30,39) (29,40)
40 40 1.48 84 84 74 74 (41,33) (40,34) (39,35)
(38,36) (37,37) (36,38)
(35,39) (34,40) (33,41)
40 48 1.48 90 99 82 81 (42,39) (41,40) (40,41)
(39,42) (38,43) (37,44)
(36,45) (35,46)
40 56 1.48 96 114 88 88 (44,44) (43,45) (42,46)
(41,47) (40,48) (39,49)
(38,50) (37,51) (36,52)
5 5 1.77 12 12 8 8 (4,4)
5 7 1.77 12 15 10 9 (4,5)
5 9 1.77 12 21 14 11 (4,7)
20 20 1.77 42 42 28 28 (14,14)
20 24 1.77 42 51 34 31 (14,17)
20 28 1.77 42 57 38 33 (14,19)
30 30 1.77 63 63 42 42 (21,21)
30 38 1.77 63 78 52 47 (21,26)
30 46 1.77 63 93 62 52 (21,31)
40 40 1.77 81 81 54 54 (27,27)
40 48 1.77 81 99 66 60 (27,33)
40 56 1.77 81 114 76 65 (27,38)
Boldfaced numbers represent the optimal points having the minimum (or the two smallest) Lp
distance(s) to the actual points minimizing N.
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Table 3.2: Minimum sample sizes when γC = γE = 1.22 under 1 to 2, 2 to 1, 1 to 1, and optimal
randomization allocation ratios for negative binomial distribution.
µC µE γ∆ 1 to 2 2 to 1 1 to 1 Optimal (nC,nE)
5 5 1.48 12 12 12 11 (7,4) (6,5) (5,6) (4,7)
5 7 1.48 15 18 14 13 (7,6) (6,7) (5,8)
5 9 1.48 15 21 16 14 (6,8)
20 20 1.48 48 48 42 41 (23,18) (22,19) (21,20)
(20,21) (19,22) (18,23)
20 24 1.48 51 54 46 45 (24,21) (23,22) (22,23)
(21,24) (20,25) (19,26)
20 28 1.48 54 63 50 48 (23,25) (22,26) (21,27)
30 30 1.48 69 69 62 61 (33,28) (32,29) (31,30)
(30,31) (29,32) (28,33)
30 38 1.48 75 87 70 69 (36,33) (35,34) (34,35)
(33,36) (32,37) (31,38)
(30,39) (29,40)
30 46 1.48 81 102 78 76 (37,39) (36,40) (35,41)
(34,42) (33,43) (32,44)
(31,45)
40 40 1.48 93 93 82 81 (44,37) (43,38) (42,39)
(41,40) (40,41) (39,42)
(38,43) (37,44)
40 48 1.48 99 108 90 89 (46,43) (45,44) (44,45)
(43,46) (42,47) (41,48)
(40,49) (39,50)
40 56 1.48 105 126 98 96 (46,50) (45,51) (44,52)
(43,53) (42,54)
5 5 1.77 12 12 8 8 (4,4)
5 7 1.77 12 18 12 10 (4,6)
5 9 1.77 12 21 14 11 (4,7)
20 20 1.77 45 45 30 30 (15,15)
20 24 1.77 45 54 36 33 (15,18)
20 28 1.77 45 63 42 36 (15,21)
30 30 1.77 69 69 46 46 (23,23)
30 38 1.77 69 87 58 52 (23,29)
30 46 1.77 69 102 68 57 (23,34)
40 40 1.77 90 90 60 60 (30,30)
40 48 1.77 90 108 72 66 (30,36)
40 56 1.77 90 126 84 72 (30,42)
Boldfaced numbers represent the optimal points having the minimum (or the two smallest) Lp
distance(s) to the actual points minimizing N.
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Table 3.3: Minimum sample sizes when γC = γE = 0.77 under 1 to 2, 2 to 1, 1 to 1, and optimal
randomization allocation ratios for normal distribution.
σ2C σ
2
E γ∆ 1 to 2 2 to 1 1 to 1 Optimal (nC,nE)
5 1 0.92 27 15 18 13 (10,3) (9,4)
5 3 0.92 27 21 20 19 (12,7) (11,8) (10,9)
5 5 0.92 27 27 24 24 (13,11) (12,12) (11,13)
5 7 0.92 33 36 30 29 (15,14) (14,15) (13,16) (12,17) (11,18)
5 9 0.92 36 48 34 33 (16,17) (15,18) (14,19) (13,20) (12,21)
10 2 0.92 51 27 34 25 (18,7) (17,8)
10 6 0.92 51 39 38 38 (24,14) (23,15) (22,16) (21,17) (20,18)
(19,19)
10 10 0.92 54 54 48 48 (26,22) (25,23) (24,24) (23,25) (22,26)
10 14 0.92 63 72 58 57 (29,28) (28,29) (27,30) (26,31) (25,32)
(24,33)
10 18 0.92 69 93 68 65 (29,36) (28,37) (27,38) (26,39)
20 12 0.92 102 78 76 75 (45,30) (44,31) (43,32) (42,33) (41,34)
(40,35) (39,36)
20 16 0.92 102 93 86 85 (46,39) (45,40) (44,41) (43,42)
20 20 0.92 108 108 96 95 (50,45) (49,46) (48,47) (47,48) (46,49)
(45,50)
20 24 0.92 114 123 104 104 (52,52) (51,53) (50,54) (49,55) (48,56)
20 28 0.92 123 144 114 113 (55,58) (54,59) (53,60) (52,61) (51,62)
(50,63) (49,64)
5 1 1.1 27 15 18 11 (9,2)
5 3 1.1 27 18 18 15 (9,6)
5 5 1.1 27 27 18 18 (9,9)
5 7 1.1 27 36 24 21 (9,12)
5 9 1.1 27 48 32 25 (9,16)
10 2 1.1 51 27 34 21 (17,4)
10 6 1.1 51 33 34 28 (17,11)
10 10 1.1 51 51 34 34 (17,17)
10 14 1.1 51 72 48 41 (17,24)
10 18 1.1 51 93 62 48 (17,31)
20 12 1.1 102 63 68 55 (34,21)
20 16 1.1 102 81 68 61 (34,27)
20 20 1.1 102 102 68 68 (34,34)
20 24 1.1 102 123 82 75 (34,41)
20 28 1.1 102 144 96 82 (34,48)
Boldfaced numbers represent the optimal points having the minimum (or the two smallest) Lp
distance(s) to the actual points minimizing N.
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Table 3.4: Minimum sample sizes when γC = γE = 5.48 under 1 to 2, 2 to 1, 1 to 1, and optimal
randomization allocation ratios for exponential distribution.
µC µE γ∆ 1 to 2 2 to 1 1 to 1 Optimal (nC,nE)
10 10 6.89 12 12 10 9 (5,4) (4,5)
10 12 6.89 12 15 12 11 (6,5) (5,6) (4,7)
10 14 6.89 15 21 14 13 (6,7) (5,8) (4,9)
20 20 6.89 42 42 34 34 (18,16) (17,17)
(16,18)
20 24 6.89 45 60 42 41 (20,21) (19,22)
(18,23)
20 28 6.89 51 81 54 49 (22,27) (21,28)
(20,29) (19,30)
30 30 6.89 90 90 76 76 (39,37) (38,38)
(37,39)








10 10 8.23 12 12 8 8 (4,4)
10 12 8.23 12 15 10 9 (4,5)
10 14 8.23 12 21 14 11 (4,7)
20 20 8.23 42 42 28 28 (14,14)
20 24 8.23 42 60 40 34 (14,20)
20 28 8.23 42 81 54 41 (14,27)
30 30 8.23 90 90 60 60 (30,30)
30 34 8.23 90 117 78 69 (30,39)
30 38 8.23 90 147 98 79 (30,49)
Boldfaced numbers represent the optimal points having the minimum (or the two smallest) Lp
distance(s) to the actual points minimizing N.
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Chapter 4
Bayesian Optimal Designs for Two-Arm Randomized Phase II Clinical Trials
with Endpoints from the Exponential family
by Wei Jiang, Jo A. Wick, Jianghua He, Jonathan D. Mahnken, and Matthew S. Mayo
Abstract
Frequentist optimal designs for two-arm randomized phase II clinical trials with outcomes from the
exponential dispersion family were proposed by Jiang et al. (2014), where the total sample sizes
are minimized under multiple constraints on the standard errors of the estimated group means.
The designs were generalized from approaches developed in Mayo et al. (2010) for dichotomous
outcomes. Compared to the frequentist method, the Bayesian approach offers a flexible way to
incorporate uncertainty in parameters of interest into considerations. In this paper, we develop
Bayesian optimal deigns for phase II clinical trials with endpoints from the exponential family
from the two previous frequentist approaches. The proposed optimal designs minimize the total
sample sizes under pre-specified constraints on the expected length of posterior credible intervals
for both group means and their difference. The designs are applicable for trials with fixed or
optimal randomization allocation ratio. Examples of method implementations are provided for
different types of endpoints in the exponential family.
Key words: Multiple constraints; Optimized design; Sample size; Posterior credible interval;
Monte Carlo; Natural conjugate prior family.
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4.1 Introduction
Sample size calculation plays an important role in clinical research since it not only affects the
success of trials but also has influence on the budget (Fosgate, 2009; Zhang et al., 2011). A recent
article by Jiang et al. (2014) describes frequentist approaches to sample size determination for
two-arm randomized phase II clinical trials with endpoints from the exponential dispersion family
using constrained optimization. Their approaches are generalized from the ideas proposed by
Mayo et al. (2010) in which the total sample sizes are optimized in the context of a binary outcome
only. For both approaches, the total sample sizes are minimized by placing multiple constraints on
the estimates of mean response in both control and experimental arms and the estimated difference
between means using standard errors of estimates. These multiple constraints, alternatively, can be
expressed in terms of confidence intervals as Lα (µC) ≤ lC, Lα (µE) ≤ lE , and Lα(µE − µC) ≤ l∆,
where Lα(.) represents the length of 100(1−α)% confidence interval for the parameter of interest,
µC and µE denote the group means, and lC, lE , and l∆ are cut-off lengths.
Similar to other frequentist methods of sample size determination, the two designs proposed
by Jiang et al. (2014) and Mayo et al. (2010) require information regarding study parameters to
compute the total sample sizes given some pre-specified constraints. In other words, the clinicians
must pre-specify the values of µC and µE based on literature, expert knowledge, or some pilot
studies, and misspecificaion of group means may lead to a poor estimate of the necessary sample
size (Mayo et al., 2010). In practice, however, there is uncertainty regarding µC and µE since they
are unknown. In many cases, for example, it is not uncommon for a clinician to only provide a
range of values for the study parameter. Under such situations, it may be inappropriate to apply
the above two designs since they treat the preliminary guesses as true values of parameters µC and
µE , and fail to incorporate the uncertainty inherent in using the best-guesses of values into sample
size optimization.
Alternatively, the Bayesian approach considers the parameters of interest as random variables,
and aims to take the uncertainty in parameters into account. In the last several decades, the
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Bayesian criteria of sample size computation generally consist of two classes. One is the decision-
theoretic or fully Bayesian approach that maximizes the pre-selected utility function, or equiv-
alently, minimizes the corresponding loss function for determination of sample size. The fully
Bayesian approach of sample size problem was first explained in details by Raiffa & Schlaifer
(1961). For other examples, see Staquet & Sylvester (1977), Sylvester (1988), Brunier & White-
head (1994), Joseph & Wolfson (1997), Pham-Gia (1997), Lindley (1997), Stallard (1998), Pham-
Gia & Turkkan (2003), and Sahu & Smith (2006). However, in the planning of a clinical trial, it
may be impossible, or, at least, is time consuming to develop a reasonable utility function or loss
function suitable for the study’s specific objectives. Also, it is very hard to develop a widely ac-
cepted loss or utility function since different studies have different needs (Adcock, 1988). There-
fore, some Bayesians recommend the performance-based or inferential-theoretic approach that
controls posterior inference for the parameter of interest with certain precision. Adcock (1997)
reviewed the inferential-theoretic approach without utility or loss functions. A comparison among
three most commonly referenced performance-based sample size criteria, the average coverage cri-
terion (ACC), the average length criterion (ALC), and the worst outcome criterion (WOC), which
compute the sample size in terms of the length and coverage of posterior credible intervals, was
provided in Cao et al. (2009). For other examples, see Adcock (1988), Joseph et al. (1995), Joseph
et al. (1997), Joseph & Belisle (1997), Tan & Machin (2002), Mayo & Gajewski (2004), Clarke &
Yuan (2006), Gajewski & Mayo (2006), M’Lan et al. (2008), and Hand et al. (2011).
In the literature, most Bayesian optimal designs for phase II studies are discussed in the context
of adaptive designs where modifications or changes on trial and/or statistical procedure are allowed
while conducting a clinical trial (Chow et al., 2008). Thall & Simon (1994) developed a Bayesian
inference-based sequential design for single-arm phase II trials where the outcome is binary and the
data are continuously monitored. Stallard (1998) developed a Bayesian decision-theoretic group
sequential design for single-arm phase II clinical studies with a dichotomous outcome using a gain
function that concentrates in the financial costs of and potential profits from the drug development
program. Thall et al. (1995) presented a Bayesian single-arm phase II trial design that allows for
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early termination of studies in terms of both adverse events and efficacy without explicit specifi-
cation of a loss function. Stallard et al. (1999) developed a single-arm phase II sequential design
that accommodates both efficacy and safety using Bayesian decision theory. Tan & Machin (2002)
described sample size calculations for single-arm two-stage phase II clinical trails with a binary
endpoint using the performance-based approach. Ding et al. (2008) proposed a decision-making
design for single-arm phase II screening trials with binary outcomes where sampling costs and
possible future payoff are incorporated using a utility function. Zhong et al. (2013) proposed a
two-stage two-arm fully Bayesian design for phase II binary response trials in which the sample
size can be reestimated at the interim analysis.
As claimed by Mayo & Gajewski (2004), it is necessary to compute a sample size before the
trial begins for practical reasons such as budgeting. Moreover, guidelines from the Food and Drug
Administration (FDA) for the use of Bayesian statistics in medical device clinical trials suggest
that a minimum pretrial sample size should be determined in terms of safety and effectiveness end-
points (Food and Drug Administration, 2010). However, because more efforts regarding Bayesian
designs are made in the context of adaptive procedures, the sample size problem assuming a fixed
trial size are less frequently discussed in the literature. Staquet & Sylvester (1977), Sylvester
(1988), and Brunier & Whitehead (1994) developed approaches of sample size calculation for
single-arm single-stage phase II trials with binary responses based on the Bayesian decision theory.
Mayo & Gajewski (2004) described an inferential-theoretic sample size approach for single-arm
single-stage phase II studies with binary endpoints. Their method was extended from the approach
developed by Tan & Machin (2002) based on diffuse prior to informative prior distributions using
various strategies that allow for incorporating pessimistic and optimistic priors into sample size
computation. This approach was further extended by Gajewski & Mayo (2006) to include a mix-
ture of informative prior distributions. However, all of these designs are for dichotomous response
and only contain one treatment arm. Randomized phase II trials are recommended when histor-
ical control data are limited or unreliable (Rubinstein et al., 2005; Mandrekar & Sargent, 2010).
Furthermore, as demonstrated in Jiang et al. (2014), other probability distributions from the ex-
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ponential family are important in the practice of phase II clinical trials. For example, Karrison
et al. (2007) designed a phase II cancer trial using a continuous outcome of change in tumor size
assumed to follow a normal distribution. Likewise, the exponential and gamma distributions are
very useful for time-to-event outcomes such as the time-to-disease progression.
Some Bayesian sample size computations have been developed for distributions from the ex-
ponential family in the context of a two-sample comparison. The difference between two binomial
proportions was considered by Joseph & Wolfson (1997) based on highest posterior density inter-
vals. Joseph & Belisle (1997) and Pezeshk (2002) applied the Bayesian inference-based approach
to determine the sample size for the differences between two normal means. Hand et al. (2011)
developed an inferential-theoretic method for sample size determination in the context of compar-
ison of two Poisson rates. However, none of these methods present designs specifically for phase
II randomized trials.
In this paper, we extend the works of Mayo et al. (2010) and Jiang et al. (2014) for two-arm
randomized phase II clinical trials to the entire exponential family from a Bayesian perspective.
For this initial development, we assume that all hyperparameters are known. An optimal design
based on hierarchical models is left for future study. Furthermore, we employ the ALC criterion
introduced by Joseph et al. (1995) to determine the sample size for the following reasons: first,
the ALC criterion has practical advantages in that neither utility nor loss function needs to be for-
mulated; second, the ALC criterion is easy to understand and implement; third, the ALC criterion
computes the sample size by controlling the average length of posterior credible intervals with a
fixed coverage rate which is, in some sense, comparable to the frequentist approaches proposed
by Mayo et al. (2010) and Jiang et al. (2014) for which design constraints can be alternatively
expressed according to confidence intervals. However, we do not advocate for using one approach
over the other.
The remainder of this manuscript is organized as follows. In section 4.2, we review the ALC
criterion. In section 4.3, the Bayesian optimal designs that minimize the total sample sizes by em-
ploying multiple constraints on the average length of posterior credible intervals of group means
62
and their difference are derived based on the natural conjugate prior family. Both optimal ratio
and fixed ratio designs are explained in this section. We continue in section 4.4 with an illustra-
tive example and two real-life phase II studies for sample-size determination using the proposed
Bayesian designs. Finally, a brief discussion is given in section 4.5
4.2 Average Length Criterion
Prior to discussing the Bayesian optimal designs, we first review the ALC criterion developed by
Joseph et al. (1995). As discussed in section 4.1, this criterion meets our needs and has practical
advantages over the decision-theoretic methods for sample size estimation.
To avoid confusion, some comments on notation are needed. We denote matrices or vectors
with boldface letters (i.e., θ ), and represent scalars by non-bolded letters (i.e., θ ). Similar to
many text books, a conditional probability density is denoted by p(.|.) and the notation p(.) is
used for a marginal distribution. Moreover, we use n, µ , and ALCα(.) to denote the sample size,
mean parameter, and average length of a 100(1−α)% posterior credible interval of a parameter
of interest, respectively. Subscript notations C and E are employed to indicate the control and
experimental arms, respectively; for example, µC stands for the mean parameter of control arm.
For the difference between means of two arms, ∆ = µE −µC is used.
Suppose that y = (y1, ...,yn) is a vector of n independent and identically distributed data points
drawn from a population indexed by θ = (θ1,θ2, ...,θk). The parameter of interest is a function of
θ denoted by µ = µ(θ ) with dimension one. If the sampling distribution is p(y|θ ), and p(θ ) is
the chosen prior density, then the posterior distribution of θ is






In practice, the marginal posterior density for µ = µ(θ ), denoted by p(µ|y), can be computed
from p(θ |y) using simulations.
The ALC criterion fixes α and determines the smallest n by guaranteeing that the expected
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length of a 100(1−α)% posterior credible interval for the parameter of interest µ weighted by the






lα(µ|y,n)p(y)dy ≤ l, (4.1)
where lα(µ|y,n) is the length of the 100(1−α)% posterior credible interval of µ given data y with
size n. Many times, it is not feasible to evaluate integral (4.1) directly; however, it can be expressed
















Therefore, if we draw a large sample {(ys,µs),s = 1, ...,S} from the joint distribution p(µ,y), the








Moreover, instead of employing the highest posterior density region, we derive the length of the
credible interval using the central posterior interval due to its easy computation and direct inter-
pretation as the posterior α/2 to 1−α/2 inter-quantile range.
4.3 Bayesian Optimal Designs
In this section, the Bayesian optimal designs that minimize the total sample sizes under multi-
ple constraints based on the ALC criterion is proposed. We start this section by refreshing the
association between the exponential family and the natural conjugate prior distributions.
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4.3.1 Exponential family and natural conjugate prior
A conjugate model is usually a good starting point for Bayesian analysis since it is easy to un-
derstand and simplifies the computation in the sense that it often leads to a closed form posterior
distribution. In general, only distributions that belong to the exponential family have natural con-
jugate prior family (Gelman et al., 2014). The review of the natural conjugate distributions and the
exponential family closely follow Gelman et al. (2014).
A family of distributions is called an exponential family if all its probability density functions
(pdf) or probability mass functions (pmf) can be expressed as





η j(θ )t j(y)
}
, (4.3)
where θ = (θ1,θ2, ...,θω),ω ≤ k is a ω-dimensional vector of parameters. Suppose that y =
(y1, ...,yn) is a vector of n samples such that the yi’s are independent and identically distributed






















where the statistic T (y) = (∑ni=1 t1(yi), ...,∑
n
i=1 tk(yi)) is a sufficient statistic for θ , and the vector
η = (η1(θ ), ...,ηk(θ )) is called the natural parameter. It has been shown that, for any sampling
distribution from the exponential family, there always exists a natural conjugate prior family, in
which all densities have the same functional form as the likelihood function (Gelman et al., 2014).
Therefore, likelihood function (4.4) reveals that the family of natural conjugate prior densities for
the exponential family follows the form





η j(θ )τ j
}
, (4.5)
indexed by known hyperparameters (τ0, ...,τk). With this conjugate prior family, the posterior
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density for θ is














Comparing the natural conjugate prior density (4.5) with the likelihood function (4.4), it is noted
that hyperparameters can be viewed as prior observations in the context of a natural conjugate
model.
4.3.2 Design constraints
Unless otherwise mentioned, yC = (y1,C, ...,ynC,C) and yE = (y1,E , ...,ynE ,E) denote nC and nE in-
dependent and identically distributed draws for the control and experimental arms, respectively,
where yi,C and yi,E are assumed following two independent exponential family distributions con-
ditional on parameters θ C and θ E . We additionally assume the joint prior distribution p(θ C,θ E)
is equal to p(θ C)p(θ E); that is, θ C and θ E are independent of each other. Equations (4.4), (4.5),
and (4.6) demonstrated in section 4.3.1 suggest that the corresponding posterior distribution for θ C
and θ E using natural conjugate prior distributions can be expressed as







































are their corresponding known hyperparam-
eters. We are interested in minimizing the total sample size in terms of the expected length of
posterior credible intervals of means and their difference; therefore, the parameters of primary in-
terest are µC = µC(θ C), µE = µE(θ E), and ∆ = µE−µC = µE(θ E)−µC(θ C), for which posterior
distributions can be derived using simulations by drawing two samples first from p(θ C|yC) and
p(θ E |yE) and then computing the values of parameters of interest for each sample point. Using
equation (4.1) derived in section 4.2, the total sample size, defined as N = nC +nE , is minimized
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lα(∆|yC,yE ,nC,nE)p(yC,yE)dyC dyE ≤ l∆. (4.9)
It is noted that quantities lC, lE , and l∆ all should be positive since the average length of a
posterior interval should be larger than zero. Performing direct calculations on the above three in-








for two arms, fixed sample sizes nC and nE , and a specified α level, the following Monte Carlo
algorithm is developed to identify nC and nE that satisfy constraints (4.7) - (4.9).
1. For s = 1, ...,S,
a. Draw θ sC and θ
s





p(yC|θ sC) and p(yE |θ sE), respectively.
b. Generate M draws of θ C and θ E from p(θ C|ysC) and p(θ E |ysE), respectively; then com-
pute µC(θ C), µE(θ E), and µC(θ C)−µE(θ E) for each draw.
c. Obtain length of credible intervals lsα(µC|ysC,nC), lsα(µE |ysE ,nE), and lsα(∆|ysC,ysE ,nC,nE)
by taking the α/2 and 1−α/2 sample quantiles from M values of µC, µE , and µE − µC
derived in step 2.
























It is noted that, under the above Monte Carlo procedure, the lengths of posterior credible inter-
vals are computed based on M posterior samples of two group means and their difference, and each
credible interval is evaluated S times. Therefore, fairly good accuracy should be retained as long
as the chosen posterior and Monte Carlo sample sizes are large enough. We carried out a small
simulation study in order to estimate what values of M and S are sufficiently large for assuring ac-
curate sample size estimates, assuming the prior and likelihood specifications are appropriate. As
shown in Figure 4.1, the center of estimated one-to-one ratio total sample size with an exponential
outcome is fairly stable as the number of independent runs (i.e., S = M) increases. The trial-to-trial
variability is relatively large for small S = M. It is fairly stable and reaches a reasonably small
magnitude when S = M ≥ 3000. This suggests that the Monte Carlo approach may work well for
the ALC criterion with relatively small S and M. In addition, one could further reduce Monte Carlo
errors by averaging over a fixed number of parallel simulation trains.
In two-arm phase II clinical trials, subjects can be randomly assigned to two arms at a fixed or
flexible allocation ratio. Thus, the proposed Bayesian optimal designs consist of two schemes: the
fixed ratio design and the optimal ratio design. Both are discussed in the following two sections.
4.3.3 Fixed ratio design
Sometimes investigators desire to assign patients to the control and experimental arms with a fixed
ratio r = c/e, where c and e are both positive integers. For example, economic efficiency can
potentially be improved by assigning more patients to the less expensive arm. When this is the
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Figure 4.1: The total sample sizes estimated for 1 to 1 design using Monte Carlo approach against
S = M for exponential distribution with Inverse-Gamma(3,40) prior for control and Inverse-
Gamma(3, 56) prior for experimental arms. The horizontal line corresponds to loess fit and vertical
line corresponds to M = S = 3000. The point positions have been jittered vertically to reduce over-
lap.
case, the desired point (nC,nE) needs to satisfy the relationship nC = rnE as well as constraints
(4.7) - (4.9). Under the assumption that the greatest common divisor for c and e is one (i.e.,
relative prime), Mayo et al. (2010) demonstrated that the set {(cd,ed) : d = 1,2,3, ...,∞} contains
all two-dimensional points such that their coordinates satisfy the ratio r = c/e.
We perform a grid search, a commonly used numerical method for searching for an optimal
point, to find the minimum sample size that satisfies design constraints and the fixed ratio r = c/e.
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To begin with, the crude starting value of d is estimated by applying the Monte Carlo simulation
algorithm discussed in section 4.3.2 with a small value of S = M (say, 500). Starting from grid
value d = 1, we first substitute (cd,ed) for (nC,nE) in three integrals under constraints (4.7) - (4.9),
and then apply the Monte Carlo algorithm to evaluate each constraint. If any of them fail to meet
the corresponding constraint (or constraints), we increase d by 1. This procedure is not terminated
until all estimated expected lengths of posterior credible intervals resulted from (cd,ed) are smaller
than or equal to pre-specified upper limits. The resulting new d (i.e., d0) is the estimated starting
value. Now we increase the number of independent runs to a larger value (S = M ≥ 3000) that
reduces trial-to-trial sample size variability to a reasonable magnitude. The fixed ratio minimum
sample size is derived by applying the following algorithm:
Step 1: Let d = d0 be the starting grid value.
Step 2: With defined c and e, replace (nC,nE) in the left-hand side of constraints (4.7) - (4.9)
by (cd,ed). Then, apply the Monte Carlo algorithm to approximate integrals under three
design constraints. If any lead to values larger than the corresponding pre-specified cutoff
levels (i.e., lC, lE , and l∆), then d = d +1; Otherwise, estimate the three integrals under the
design constraints using d = d−1 to evaluate whether current d value is actually larger than
the desired minimum.
Step 3: Repeat step 3 until the minimum d is attained. The minimum sample size for c : e
fixed ratio design is (nC,nE) = (cd,ed).
4.3.4 Optimal ratio design
When there is no limitation on the allocation ratio, the minimum sample size needs to satisfy
constraint (4.7) - (4.9) only. Again, the grid search method is conducted to obtain the minimum
sample size under the design constraints. However, for the optimal ratio design, the grid point
(nC,nE) is two-dimensional and the standard grid search method evaluates all combinations of grid
values of nC and nE . Thus, as the number of values taken by nC and nE increases, the number of
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grid points inflates considerably and searching speed could be extremely slow. For example, when
both nC and nE range from 1 to 10 by increments of 1, the total number of grids is 102 = 100. If
both nC and nE take integer values from 1 to 30, the total number of grids overwhelmingly increases
to 302 = 900. Therefore, we propose a rapid grid search method that lightens the computational
burden by efficiently reducing the number of grid points.
Figure 4.2 displays the rapid grid search procedure. To begin with, the Monte Carlo simulation
procedure and the standard grid search method are conducted to obtain the minimal sample size
(n(4.7)C ,n
(4.8)
E ) under constraints (4.7) and (4.8). As discussed previously, a small S = M value
may be helpful for targeting an efficient starting value when the standard grid search method is







Be aware that (n(4.7)C ,n
(4.8)
E ) reaches the minimal sample size if it does not violate constraint (4.9).
Now, we add one sample at a time to the experimental arm and evaluate constraint (4.9) for each
grid point using the Monte Carlo simulation until the approximated expected length of the posterior
credible interval for (µE−µC) is smaller than l∆. This gives us an initial optimal candidate (n0C,n1E).
We next add one sample to n0C and withdraw one sample from n
1
E , and again perform the Monte
Carlo simulation to estimate the mean length of the posterior credible interval in constraint (4.9).
If it is larger than the cutoff level l∆, additional samples are added and removed, respectively, to
the control and from the experimental arms one at a time until the estimated average length of
the posterior credible interval of (µE − µC) satisfies constraint (4.9). We then make subsequent
searches by decreasing one sample at a time from the experimental arm until the grid point fails to
meet constraint (4.9). This yields the second optimal candidate (n1C,n
2





E),k = 1, ...,k
}
are obtained by repeating the above steps; this procedure is
terminated if nkE − 1 is smaller than n0E . We give the algorithm of the proposed rapid grid search
method as follows:
Step 1: Use the Monte Carlo approximation and the standard grid search method to derive
the minimum sample size under constraints (4.7) and (4.8). Consider this point as the starting
grid point and denote it by (n0C,n
0
E). If ÂLCα(∆|n0C,n0E) ≤ l∆, then (n0C,n0E) is the optimal
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point under the optimal ratio design; otherwise, go to step 2.
Step 2: For i = 1,2, ...,∞, evaluate ÂLCα(∆|nC,nE + i) until it is no greater than l∆. Suppose
i = I, then report (nC,nE) = (nC,nE + I) as an optimal candidate and proceed to step 3.
Step 3: Add samples to the control arm and remove samples from the experimental arm one
at a time until the updated ÂLCα(∆|nC,nE) is less than or equal to l∆. Then make subsequent
searches downwards by withdrawing one sample at a time from the experimental arm until
the updated ÂLCα(∆|nC,nE) is greater than l∆. The last grid point that gives an estimated
average length of no greater than l∆ is a candidate of optimal point.
Step 4: Repeat step 3 until nE is less than n0E .
For the optimal ratio design, the grid search method may lead to multiple optimal points with
the same minimum total sample size but different allocation schemes. During clinical practice,
investigators can choose the point that most satisfies their needs. For example, a design that assigns
more patients to the less expensive arm may be preferred for the sake of reducing the trial budget.
4.4 Application
In section 4.3, we demonstrated the Bayesian optimal designs for two-arm randomized phase II
clinical trials, which optimize the total sample sizes under multiple constraints on the average
length of posterior credible intervals of two group means and their difference. In this section, we
first briefly discuss strategies for prior elicitation in section 4.4.1. We then continue in section
4.4.2 with an illustrative example that explains implementations of the proposed models on the ex-
ponential distribution. Finally, we conclude this section with two real-life phase II clinical trials for
which the primary outcome for one trial is normally distributed and the other follows the Bernoulli
distribution. R functions are developed and used for computing sample sizes in all examples.
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Figure 4.2: Rapid grid search procedure. The searching process stops when the grid value for nE
is less than n0E .
4.4.1 Prior elicitation
In this subsection, we briefly illustrate our general approach for eliciting natural conjugate prior
distributions. Depending on the amount of information provided from the prior distribution, priors
can be classified into informative, weakly informative, and non-informative relative to the likeli-
hood. More specifically, informative priors express relatively small prior uncertainty about param-
eters; weakly informative priors convey relatively less certain information about likely values of
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parameters; and the non-informative priors reflect high prior uncertainty (Gelman et al., 2014).
Many authors have discussed approaches of prior elicitation, including Spiegelhalter et al.
(2004), O’Hagan et al. (2006), and Johnson et al. (2010). As pointed out by Spiegelhalter et al.
(2004), these different approaches can be classified into four categories: (1) informal discussion,
(2) structural interviewing and formal pooling of opinion, (3) structured questionnaires, and (4)
computer-based elicitation. In this paper, we employ the method discussed in Mayo & Gajewski
(2004) which includes two steps for eliciting priors. First, the center value of the chosen prior
is elicited by asking a clinician questions such as, “ What is the most likely average value that
you expect to observe for the primary endpoint?” The response to this question can correspond to
the prior mean. Other commonly used center measurements include the median and mode. The
second step is to elicit the uncertainty in the center value by asking clinicians questions such as,
“How uncertain is the center value you provided?” Depending on different answers provided from
clinicians, the uncertainly in center value can be elicited in terms of the prior sample size or the
width of a 100(1−α)% credible interval from the prior distribution. The computer plot of the pdf
or pmf of the corresponding conjugate distribution may be helpful for clinicians to conceptualize
the prior (Thall & Simon, 1994).
Gelman et al. (2014) demonstrated that hyperparameters of natural conjugate priors can be
interpreted as additional observations. Thus, we elicit prior densities in terms of the prior mean
and prior sample size. For example, informative priors are built by fixing the prior mean and
choosing a large prior sample size relative to the size of the experiment. Conversely, weakly infor-
mative priors are constructed using a small prior sample size relative to the size of the experiment.
Following this idea, the hyperparameters for both control and experimental arms are obtained by
specifying the prior means and the prior sample sizes which parameterize two prior distributions
to properly reflect the experts’ opinion. The pre-specified prior information and the solutions to
these simultaneous equations fully specify the prior distributions.
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4.4.2 Exponential endpoint
The exponential distribution is a natural and commonly used model in phase II clinical trials when
the data are in the form of waiting time. For instance, the primary clinical endpoint in many phase
II oncology trials is a time-to-event outcome such as the disease-free or overall survival.
4.4.2.1 InverseGamma-Exponential model
When the observations yg = (y1,g, ...,yng,g) provided for arm g under the experiment of consider-
ation are independent and identically exponentially distributed with scale parameter θg, g =C,E,












where c(θg) = 1/θg, η1(θg) =−1/θg and ∑
ng
i=1 t1(yi,g) = ∑
ng
i=1 yi,g with k = ω = 1. Equation (4.5)












where τ0,g = αg+1 and τ1,g = βg. This is an Inverse-Gamma density with shape parameter αg and
rate paramter βg. Using equation (4.6), the corresponding posterior distribution for θg is





According to Gelman et al. (2014), the above two hyperparameters, in some sense, can be
explained as αg + 1 exponential observations with total waiting time βg. Recall that the mean
parameter of an exp(θg) outcome is µg(θg) = θg, g =C,E; therefore, the three design constraints
under which the total sample size is minimized are: ALCα(θC|nC) ≤ lC, ALCα(θE |nE) ≤ lE , and
ALCα(∆|nC,nE) = ALCα(θE −θC|nC,nE)≤ l∆.
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4.4.2.2 Illustrative example
We first elicit all four hyperparameters, αC,βC,αE , and βE , in order to perform the Monte Carlo
simulation. For illustrative purposes, the InverseGamma-Exponential model is carried out with
E(θC) = βC/(αC − 1), the prior mean of the control arm, equal to 20 and 30, and E(θE) =
βE/(αE − 1), the prior mean of the experimental arm, equal to 24 and 28 when E(θC) = 20,
and equal to 34 and 38 when E(θC) = 30. In order to study the influence of prior specification
on sample size estimates, we place both weakly informative and informative priors on θC and θE .
More specifically, the prior sample sizes of both arms are 4 for the weakly informative model, and
are 12 for the informative model. Suppose that the estimated total sample size of an experiment is
N, the ratios 8/(8+N) and 24/(24+N), in some sense, can be viewed as the percentages of in-
formation contributed by the weakly informative and informative prior distributions, respectively.
Finally, regarding the average length cutoff levels for α = 0.05, we set lC = 21.5, lE = 21.5, and
l∆ = 27.
The computed minimum sample sizes under the one-to-one, one-to-two, and optimal ratios
are reported in Table 4.1. Suppose that one has an actual phase II study where the standard of
care has a prior mean of E(θC) = 20, and you expect a new treatment to have a prior mean of
E(θE) = 28. For the informative model, the solution to the prior Inverse-Gamma parameters are
αC = 11, βC = 200, αE = 11, and βE = 280. Under the constraints used in Table 4.1, the optimal
ratio design results in a total of 34 subjects; the one-to-one design results in 18 subjects in each
arm (36 total subjects); and the one-to-two design results in 12 subjects in the standard of care arm
and 24 subjects in the experimental arm (36 total subjects). These imply that approximately 40%
information is contributed by the informative prior distributions under each design consideration.
Notice that the optimal ratio design produces several different allocation schemes. If investiga-
tors want to assign more patients to the more promising experimental arm, the allocation scheme
(11,23) may be chosen. In Table 4.1, we also calculate the optimal sample sizes under the weakly
informative model. Not surprisingly, the resulting sample sizes are larger than the ones under the
informative model. Consider again the sample size calculation in the case of E(θC) = 20 and
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Table 4.1: Bayesian optimal sample sizes for lC = lE = 21.5 and l∆ = 27 under 1 to 1, 1 to 2, and
optimal randomization allocation ratios for exponential distribution.
E(µC) E(µE) Prior 1 to 1 1 to 2 Optimal (nC,nE)
20 24 01 26 27 26 (9,17) (10,16) (11,15) (12,14)
(13,13) (14,12)
20 28 01 36 36 34 (11,23) (12,22) (13,21) (14,20)
(15, 19)
30 34 01 74 78 74 (30,44) (31,43) (32,42) (33,41)
(34,40) (35,39) (36,38) (37,37)
(38,36)
30 38 01 86 90 85 (35,50) (36,49) (37,48) (38,47)
(39,46)
20 24 02 46 48 45 (18,27) (19,26) (20,25) (21,24)
(22,23) (23,22)
20 28 02 54 57 53 (21,32) (22,31) (23,30) (44,29)
30 34 02 96 105 96 (42,54) (43,53) (44,52) (45,51)
(46,50) (47,49) (48,48)
30 38 02 110 114 109 (44,65) (45,64) (46,63) (47,62)
(48,61) (49,60) (50,59) (51,58)
(52,57) (53,56)
Column “Prior” corresponds to different prior distributions where “01” represents the informative
prior (prior sample sizes of both arms are 12) and “02” represents the weakly informative prior
(prior sample sizes of both arms are 4).
E(θE) = 28. When the prior sample sizes of both arms are 4, the solution to the hyperparameters
are αC = 3, βC = 40, αE = 3, and βE = 56. Using the Monte Carlo algorithm, the optimal ratio
design, one-to-one, and one-to-two designs would, respectively, require enrolling 53, 54, and 57
subjects, implying that approximately 10% information is contributed by the weakly informative
prior distributions under each design consideration.
In addition, we contrast the frequentist optimal designs from Jiang et al. (2014) with the pro-
posed Bayesian optimal designs when the outcome is exponentially distributed. In the context
of Bayesian optimal designs, we seek the minimal sample size to ensure that the 95% posterior
credible intervals for means of control and experimental arms and their difference have lengths no
wider than lC, lE , and l∆, respectively. Alternatively to 95% posterior credible intervals, the optimal
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Table 4.2: Optimal sample sizes for lC = lE = 21.5 and l∆ = 27 under 1 to 1, 1 to 2, and optimal
randomization allocation ratios for exponential distribution using frequentist approaches (Jiang
et al., 2014).
µC µE 1 to 1 1 to 2 Optimal (nC,nE)
20 24 42 45 41 (20,21) (19,22) (18,23)
20 28 54 51 49 (22,27) (21,28) (20,29) (19,30)
30 34 88 96 87 (44,43) (43,44) (42,45) (41,46) (40,47) (39,48)
(38,49) (37,50)
30 38 100 105 98 (47,51) (46,52) (45,53) (44,54) (43,55) (42,56)
(41,57) (40,58)
frequentist approaches search for the total sample size that leads to 95% confidence intervals for
the control and experimental means and their difference with lengths being narrower than or equal
to lC, lE , and l∆, respectively. Unlike the Bayesian methods, the frequentist models do not take the
uncertainty in values of θC and θE into account. Table 4.2 presents the sample sizes based on the
frequentist designs in which, for comparison purposes, specified values of θC and θE are chosen
to match prior means of these two parameters listed in Table 4.1. Similarly, constraint values of
lC = lE = 21.5 and l∆ = 27, the same as those employed by the Bayesian methods, are used for
computing the frequentist sample sizes. Observe that the sample sizes displayed in Table 4.2 are
smaller than the ones obtained from the weakly informative model but are larger than the ones
based on the informative priors for all one-to-one, one-to-two, and optimal ratios.
4.4.3 Normal endpoint
The normal distribution is often employed in designs where the original continuous outcome is
of interest rather than the categorization of this continuous variable. For example, the tumor size
ratio, instead of the response rate, is sometimes treated as the primary endpoint. Lavin (1981)
demonstrated that the log tumor size ratio approximately followed the normal distribution.
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4.4.3.1 Normal-Inverseχ2 model
Under the two-parameter normal sampling model, we have θ g = (µg,σ2g ), g=C,E. The likelihood
function in the exponential family form (4.4) for a vector yg of ng independent and identical normal





























where c(θ g) = (1/σ2g )
1/2, η1(θ g) = µg/σ2g , η2(θ g) = −1/(2σ2g ), ∑
ng











g ) with k = ω = 2. Recall from equation (4.5) that the natural con-
jugate prior for θ g has the same functional form as the above likelihood; therefore, the family of

























where τ0,g = αg + 3, τ1,g = κgζg, and τ2,g = αgβg +κgµ2g +κgζ
2


























Therefore, the corresponding conjugate prior density for θ g = (µg,σ2g ) is a mixture of the
marginal prior distribution σ2g ∼ Inverse-χ2(αg,βg) and the conditional prior distribution µg|σ2g ∼
N(ζg,σ2g/κg). We label this the Normal-Invχ
2(ζg,σ
2
g/κg;αg,βg), where ζg and σ
2
g/κg represent
location and scale of µg with κg prior measurements, and the last two parameters can be viewed
as αg prior observations with βg average squared deviation (Gelman et al., 2014). After using
equation (4.6) and some algebraic manipulation, it can be shown that the joint posterior density for
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θ g = (µg,σ
2
g ) is
















κn,g = κg +ng,
αn,g = αg +ng,








Notice that both the prior information and the information provided by the data are contained in
the parameters of the joint posterior distribution. For instance, the parameter ζn,g can be explained
as a weighted average of the prior mean ζg and the sample mean ȳg. Furthermore, because the mean
parameter of a normally distributed endpoint is µg(θ g) = µg, g =C,E, the design constraints are
ALCα(µC|nC)≤ lC, ALCα(µE |nE)≤ lE , and ALCα(∆|nC,nE) = ALCα(µE −µC|nC,nE)≤ l∆.
4.4.3.2 Illustrative example: change in tumor size as endpoint
A recently published randomized phase II clinical study of the effect of sorafenib and erlotinib
in non-small-cell lung cancer (Karrison et al., 2007) treats tumor size as a continuous variable
for assessing antitumor activity. The control arm of this study is 150 mg erlotinib daily plus
placebo, and the two treatment arms are 150 mg erlotinib daily plus 200 mg and 400 mg sorafenib
twice daily, respectively. The ratio of tumor size at 8 months after treatment to that at baseline
is the primary endpoint, and the author assumes that the log of this ratio comes from a normal
distribution. In this paper, we use the control arm and the 150 mg erlotinib plus 400 mg sorafenib
to illustrate the proposed optimal designs. Based upon four previous single-arm studies of erlotinib
or sorafenib, this study assumes that the mean log ratio is 0.05 for the placebo control arm and is
-0.13 for the chosen experimental arm. In addition, this trial assumes an equal variance of 0.1197
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for the log ratio by pooling the variance estimates from the four previous trials. For more details
about this phase II cancer trial, see Karrison et al. (2007).
In order to use the ALC criterion, we set the cutoff levels for 95% credible intervals (α = 0.05)
to be lC = lE = 0.2 and l∆ = 0.28. Following the elicitation strategy discussed in section 4.4.1 and
using the information provided in the above phase II trial, we assume that E(µC|σ2C) = ζC = 0.05
and E(σ2C) = (αCβC)/(αC− 2) = 0.1197 for the control arm, and E(µE |σ2E) = ζE = −0.13 and
E(σ2E) = (αEβE)/(αE − 2) = 0.1197 for the experimental arm. Moreover, we let αC = αE = 5
which, in some sense, can be viewed as information of five prior observations provided for σ2C and
σ2E . For comparative purposes, we report the optimal total sample sizes using both weekly informa-
tive and informative priors for mean parameters µC and µE . In more detail, we let κC = κE = 0.001
for the weakly informative model. This means that nearly no prior information is provided for µC
and µE . In this case, the optimal ratio design requires enrolling 85 total subjects where allocation
schemes include (40,45), (41,44), (42,43), (43,42), (44,41), and (45,40); the one-to-one design
leads to 86 total subjects among which each arm contains 43 subjects; and the one-to-two design
results in 120 total subjects where 40 individuals are assigned to the control and 80 individuals
are assigned to the experimental arm. On the contrary, an informative model with κC = κE = 10
results in 66, 66, and 90 total subjects for the optimal, one-to-one, and one-to-two ratios, re-
spectively. Similar to the weakly informative model, the optimal ratio design using informative
priors produces several allocation schemes including (30,36), (31,35), (32,34), (33,33), (34,32),
(35,31), and (36,30). As expected, the total sample sizes produced under weakly informative
model are larger than the ones obtained from informative model. Figure 4.3 shows the one-to-one
ratio sample size determination for the normal endpoint based on informative priors. Further, it
should be noticed that, in the context of Normal-Inverseχ2 model, the resulting total sample size is
irrelevant to the location of center value of µC and µE but affected by the uncertainty in the center
values. This is because the variance and mean of the normal distribution are independent of each
other.
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Figure 4.3: Total sample size determination for 1 to 1 design by ALC for normal distribution with
ζC = 0.05, κC = 10, αC = 5, and βC = 0.07182 for control arm, and ζE =−0.13, κE = 10, αE = 5,
and βE = 0.07182 for experimental arm. The horizontal line above corresponds to l∆ = 0.28 and
the horizontal line below corresponds to lC = lE = 0.2. In the legend, constraint 4.7 stands for
ALCα(µC|nC) ≤ lC, constraint 4.8 stands for ALCα(µE |nE) ≤ lE , and constraint 4.9 stands for
ALCα(∆|nC,nE)≤ l∆.
4.4.4 Bernoulli endpoint
The Bernoulli distribution is one of the most commonly used models in phase II oncology clin-
ical trials where the primary outcome, for example, may be whether a partial or complete tumor




We let yg = (y1,g, ...,yng,g) be a vector of independent and identically distributed Bernoulli draws
for arm g with probability parameter θg, g =C,E. Then the likelihood function for this family can













where c(θg) = 1− θg, η1(θg) = log{θg/(1− θg)}, and ∑
ng
i=1 t1(yi,g) = ∑
ng
i=1 yi,g with k = ω = 1.
Equation (4.5) reveals that the natural conjugate prior density should be of the same form as the











where τ0,g = αg +βg−2 and τ1,g = αg−1. After several steps simple algebra, this natural conju-




which is a beta density with parameters αg and βg. Using equation (4.6), the corresponding poste-














Be aware that the above two hyperparameters can be explained as αg − 1 prior successes
and βg − 1 prior failures for a particular sequence of αg + βg − 2 prior experiments (Gelman
et al., 2014). In addition, in the context of the Beta-Bernoulli model, the parameter of interest
is µg(θg) = θg, g =C,E; thus the three constraints under which the total sample size is minimized
are ALCα(θC|nC)≤ lC, ALCα(θE |nE)≤ lE , and ALCα(∆|nC,nE) = ALCα(θE −θC|nC,nE)≤ l∆.
83
4.4.4.2 Illustrative example: MK-0646 IMPACT study
A recent phase II clinical trial at the University of Kansas Medical Center, the MK-0646 IMPACT
study, aimed to compare the response rates of two chemotherapy treatments in non-small cell lung
cancer. The standard of care of this study is pemetrexed and cisplatin, and the experimental arm is
the combination of pemetrexed/cisplatin with MK-0646. The number of patients was found using
the optimal randomized phase II design based upon multiple constraints (Mayo et al., 2010; Jiang
et al., 2014). More specifically, they seek the minimal sample size to guarantee that the length of a
90% confidence interval for the response rate in each arm is no wider than 0.33, as well as a 90%
confidence interval for the difference between the response rates has a length no greater than 0.4.
Moreover, the expected response rate of 0.3 is used for the control arm, and 0.45 is the expected
rate for the experimental arm. As a result, the optimal, one-to-one, and two-to-one ratios lead to
62, 62, and 69 total patients, respectively.
Instead of confidence intervals as used in the original study design, the proposed Bayesian
approaches minimize the total sample sizes based on posterior credible intervals. Using the prior
information provided above, we assume that E(θC) =αC/(αC+βC) = 0.3 and E(θE) =αE/(αE +
βE) = 0.45. Now suppose that we have a strong belief in the prior knowledge about θC (standard
care) but are not confident in the prior information for θE (new treatment). This may be reflected by
placing an informative prior on the control arm but a weakly informative prior on the experimental
arm. More specifically, we let αC +βC = 12 which corresponds to 10 prior observations, and αE +
βE = 2 which corresponds to no prior observation. In this case, solutions to the hyperparameters
are αC = 3.6, βC = 8.4, αE = 0.9, and βE = 1.1. In addition, we use the same cutoff levels as
those used in the frequentist methods; that is, lC = lE = 0.33 and l∆ = 0.4. Under the specified
constraints, the optimal ratio design leads to 34 total patients; the one-to-one design requires 36
total patients, 18 patients in each arm; and the two-to-one design results in 42 total patients where
28 patients are randomized to the control and 14 patients are randomized to the experimental arm.
As usual, several allocation schemes are produced by the optimal ratio design including (11,23),
(12,22), (13,21), (14,20), and (15,19). For comparison purposes, we also compute the sample
84
sizes by placing non-informative priors on both study groups. As a result, the non-informative
model with αC = βC = αE = βE = 1 leads to 41, 42, and 45 total subjects for optimal, one-to-
one, and two-to-one ratios. In this case, the allocation schemes of the optimal ratio design contain
(18,23), (19,22), (20,21), (21,20), (22,19), and (23,18). Not surprisingly, we see that the sample
sizes under non-informative model are larger than the ones obtained from more informative priors.
Unlike previous examples, however, both prior settings lead to much smaller sample sizes than
those obtained from the frequentist approaches. This may be because the flat non-informative
priors still provide some information by restricting θs to values between 0 and 1. Figure 4.4
shows the sample size determination of one-to-one ratio design for binary outcomes based on the
informative priors.
4.5 Discussion
In this paper, we develop Bayesian optimal designs and discuss their use for designing two-arm
randomized phase II clinical trials with endpoints from distributions in the exponential family. The
proposed designs minimize the sample sizes by placing multiple constraints on the average length
of posterior credible intervals of two group means and their difference. We employ the ALC
criterion to determine our sample size due to its practical advantage that the sample size can be
calculated without specifying a loss or utility function. Since it is not feasible to present a general
closed form formula for ALC, we estimate the average length of posterior credible intervals and
the sample size using the Monte Carlo method. Our simulation study shows that the Monte Carlo
method performs well with relatively small values of S and M. Moreover, we develop a rapid grid
search method to reduce the computational burden.
Unlike the optimal designs proposed by Mayo et al. (2010) and Jiang et al. (2014) using fre-
quentist approaches, the proposed Bayesian methods can take uncertainty in parameters of interest
into account through prior distributions. We focus on the natural conjugate prior family because
many probability distributions from the exponential family, such as the Bernoulli, normal, Poisson,
and exponential, are important in the practice of phase II clinical trials and, according to Gelman
85
Figure 4.4: Total sample size determination for 1 to 1 design by ALC for Bernoulli distribution with
Beta(3.6, 8.4) prior for control arm and Beta(0.9, 1.1) prior for experimental arm. The horizontal
line above corresponds to l∆ = 0.4 and the horizontal line below corresponds to lC = lE = 0.33. In
the legend, constraint 4.7 stands for ALCα(µC|nC)≤ lC, constraint 4.8 stands for ALCα(µE |nE)≤
lE , and constraint 4.9 stands for ALCα(∆|nC,nE)≤ l∆.
et al. (2014), the only class of distributions that has natural conjugate prior distributions is the
exponential family. Several other advantages associated with the conjugate family include: the
posterior distribution of conjugate models has a closed form density so we can easily derive quan-
tities of interest analytically; and the hyperparameters of conjugate prior distributions are easy to
understand because, in some sense, they can be interpreted as prior observations (Gelman et al.,
2014). However, one limitation is that some prior beliefs cannot be fully described by conjugate
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priors. For example, a beta prior cannot be bimodal. Moreover, as is shown in section 4.4, the
amount of prior information has significant influence on the resulting sample size. Smaller sample
sizes result from more precise priors whereas diffuse priors lead to larger trials. Therefore, incor-
porating prior information that properly reflects experts’ opinions is the foundation of our Bayesian
optimal designs, and strong prior opinion can reduce the size of a study.
In this paper, we do not consider adaptive or sequential design where observations made during
the trial can dynamically modify the subsequent trial design. Rather, we provide the Bayesian
optimal designs that compute the sample sizes assuming one stage. This is necessary for many
investigators because a single sample size is important for practical purposes, such as planning the
number of patients to recruit, as well as preparing a budget for a trial. However, early stopping
rules can be incorporated into our designs so that a trial can terminate early due to efficacy or
futility. One idea is to set the total sample size produced by the proposed Bayesian designs as the
maximum number of accrued patients of a phase II study, as suggested by Berger (1985). After
obtaining the first m observations, a stopping rule can be evaluated, for example, in terms of the
posterior probability that µE exeeds µC based on the data accumulated so far. In conclusion, the
proposed Bayesian optimal designs are very flexible and useful, and can be easily employed when
conducting two-arm randomized Phase II clinical trials.
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Chapter 5
Summary and Future Directions
The most important studies for developing novel treatments are the clinical trials where statistics
play a crucial and indispensable role since the vital feature of clinical research is to generalize sta-
tistical inference for the results of new treatments from a limited sample to the general population
of patients (Pocock, 2006). This motivated us to concentrate in improving the statistical practice
and designs for single-stage two-arm randomized phase II trials.
In this dissertation, we develop an R package called Sample.Size based on the optimal designs
proposed in Mayo et al. (2010) to accelerate, facilitate, and improve the statistical practice in phase
II studies. This package can be used to design oncology phase II trials aiming to estimate response
rates in the control and experimental arms and the difference between the two rates with various
levels of precision using standard errors as constraints. It is also helpful in designing clinical
studies attempting to control precision level of estimates for one proportion only, or the difference
between two proportions only, or both proportions but not the difference.
Many probability distributions from the exponential family are important in the practice of
phase II clinical trials. Since the original designs developed by Mayo et al. (2010) are limited to
trials with dichotomous endpoints only, we develop optimal designs from a frequentist perspective
for two-arm randomized phase II clinical trials with endpoints from the exponential dispersion
family. The proposed designs are more broadly applicable to other types of commonly used study
measures in phase II studies including the normal, exponential, gamma, and Poisson distributions.
It is very flexible in that both fixed and flexible allocation ratios are allowed, and can be readily
implemented using current software such as SAS and R. Similar to other frequentist methods,
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however, the proposed designs are incapable of incorporating the uncertainty inherent in unknown
parameters into sample size optimization, and misspecification of these values may lead to a less
than optimal design.
Bayesian approaches offer a flexible way to incorporate uncertainty in parameters of interest
into considerations. Therefore, we further improve the two frequentist designs to the entire ex-
ponential family from a Bayesian perspective. The proposed Bayesian designs use the natural
conjugate prior family to optimize the total sample sizes under pre-specified constraints on the ex-
pected length of posterior credible intervals for both group means and their difference. It inherits
the advantages of the two frequentist approaches for which both fixed and optimal allocation ratio
designs are integrated. In addition, the proposed Bayesian designs can be easily implemented when
conducting two-arm randomized phase II clinical trials. However, similar to many other Bayesian
approaches, the amount of prior information significantly affects the resulting sample sizes, and
misleading results may be produced if chosen priors are inappropriate. Therefore, eliciting a prior
that properly reflects experts’ beliefs is the foundation of the proposed Bayesian designs. Another
limitation associated with the proposed approaches is that prior beliefs sometimes cannot be fully
described by conjugate priors.
There are several topics that attract our attention for future studies. First, in this dissertation,
an R package is only developed for Mayo’s optimal designs (Mayo et al., 2010) which are limited
to dichotomous outcomes. Both frequentist and Bayesian extensions developed in this dissertation
are more broadly applicable to phase II trials with endpoints from the exponential family. It is
also necessary to develop R packages for these two proposed designs. Second, when the primary
endpoints in phase II trials are time-to-event measures, it is quite often that outcomes of some sub-
jects cannot be observed after a period of time. So it is necessary to extend our current work for
phase II clinical trials to designs allowing for incorporating censored observations. Third, for the
generalized Bayesian optimal designs, all hyper-parameters are assumed having known and fixed
values. The flexibility can be strengthened by extending current Bayesian approaches to designs
based on hierarchical models. Fourth, the proposed Bayesian optimal designs are based on the
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natural conjugate prior family to which one limitation is that some prior beliefs cannot be fully
described by conjugate priors. Therefore, it is beneficial to extend the current work to Bayesian
designs without assuming conjugacy. Fifth, both Bayesian and frequentist optimal designs com-
pute the total sample sizes assuming one stage. When primary endpoints in phase II trials are
rapidly observable, the sequential or adaptive designs may be more appropriate due to the ethical
and economy considerations. So it is beneficial to extend the current work to designs for phase II
trials with stopping rules and sample size reestimation.
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